Curriculum Vitae

PROF. DR. HO GWO FUANG

Professor
  • Dean Office
    Faculty of Medicine
  • 03-79493037

BIOGRAPHY


Dr Ho Gwo Fuang is a professor and clinical oncologist at Universiti Malaya Medical Centre and Universiti Malaya Specialist Centre, Kuala Lumpur, Malaysia. He was trained at Barts and The London National Health Service (NHS) Trust and The Royal Marsden NHS Trust in London. He attained his Certificate for Completion of Specialist Training (CCST) in 2007 and joined the Faculty of Medicine at Universiti Malaya. He received the Joint Commission International (JCI) Outstanding Young Malaysian Award in 2009 for medical innovation. His research interests involve breast, gastrointestinal, and hepatobiliary cancers. He co-authored the Pan-Asian Adapted ESMO Clinical Practice Guidelines for hepatocellular carcinoma (2020) and ASCO Resource Stratified Guideline for Early Detection for Colorectal Cancer (2019) and Treatment of Patients with Early Stage Colorectal Cancer Resource Stratified Guideline (2019). He is involved in many national and international collaborative research work, as well as the training of new oncologists in Malaysia.

AREAS OF EXPERTISE


  • ONCOLOGY
    Cancer therapeutics: chemotherapy, biological therapy, targeted therapy, radiotherapy, radiosurgery, brachytherapy, radio-isotopes treatment

ACADEMIC QUALIFICATION


  • FRCR, THE ROYAL COLLEGE OF RADIOLOGISTS, UK (2005), (Lain-Lain)
    Royal College of Radiologist, London
  • MRCP, THE ROYAL COLLEGE OF PHYSICIANS, UK (2001), (Lain-Lain)
    Royal College of Physicians of Edinburgh, United Kingdom
  • MBBS, MANCHESTER UNIVERSITY, UK (1998), (Bachelor of Medicine & Bachelor of Surgery)
    University of Manchester, United Kingdom
  • BSC (MEDICAL SCIENCE), UNIVERSITY OF ST ANDREWS, SCOTLAND (1995), (Sains Perubatan)
    St. Andrews University, Scotland

ADMINISTRATIVE DUTIES


  • Oncology lead, Cigmit Project UMMC
    08 Feb 2012 - present (University Malaya)
  • Manager
    04 Jan 2010 - present (University Malaya)
  • Head of Unit
    06 Mar 2021 - 31 Dec 2023 (Clinical Oncology Unit, Faculty of Medicine)
  • Organizing Committee-Masterclass in Systemic Cancer Therapy-Understanding the science behind therapy.
    02 Dec 2019 - 12 Sep 2020 (University Malaya)
  • Acting Secretary
    16 Dec 2018 - 15 Dec 2019 (National)
  • Acting Secretary
    10 May 2017 - 09 May 2018 (National)
  • Chairman
    01 Oct 2013 - 31 Jul 2015 (University Malaya)
  • Programme Coordinator
    05 Mar 2009 - 18 Jan 2010 (University Malaya)

MEMBERSHIPS


  • SENIOR CONSULTANT IN CLINICAL ONCOLOGY , MEMBER
    2022 to 2024 (University)
  • MAJLIS PROFESOR NEGARA, MEMBER
    Since 2022 (National)
  • INTERNATIONAL JOURNAL OF RADIOGRAPHY IMAGING AND RADIATION THERAPY, EDITORIAL BOARD MEMBER
    Since 2018 (International)
  • JOURNAL OF CANCER RESEARCH, EDITORIAL BOARD MEMBER
    Since 2017 (International)
  • ESMO MEMBERSHIP FOR DEVELOPING COUNTRY UPPER, MEMBER
    2016 to 2024 (International)
  • EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)-MEMBER, MEMBER
    2015 to 2024 (International)
  • TOGETHER AGAINST CANCER ASSOCIATION MALAYSIA (TAC), ORGANIZATION COMMITTEE, COMMITTEE MEMBER
    2022 to 2023 (National)
  • UNIVERSITY MALAYA MEDICAL CENTRE, CONSULTANT
    2019 to 2022 (University)
  • EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, ACTIVE MEMBER
    2020 to 2021 (International)
  • MALAYSIAN MEDICAL COUNCIL, SPECIALIST REFER
    2018 to 2020 (National)
  • MEDICAL PROTECTION SOCIETY, MEMBER
    2019 to 2019 (National)
  • PERSATUAN GUOLIN QIGONG MALAYSIA, MEDICAL OFFICER
    2017 to 2019 (National)
  • MALAYSIAN ONCOLOGICAL SOCIETY, COUNCIL MEMBER
    2013 to 2018 (National)
  • ASCO (AMERICAN SOCIETY OF CLINICAL ONCOLOGY) RESOURCE-STRATIFIED COLORECTAL CANCER EXPERT PANEL, PANEL MEMBER
    2017 to 2017 (International)
  • ANNUAL SCIENTIFIC CONFERENCE OF THE MALAYSIAN ONCOLOGICAL SOCIETY 2017 (ASCOMOS 2017), SCIENTIFIC COMMITTEE
    2017 to 2017 (National)

AWARD AND STEWARDSHIP


  • CIC Grants Top 10 Recipients (2022)
    Universiti Malaya, 2023 (University)
  • Web of Science Highly Cited Paper Series 2023-10
    Essential Science Indicators, 2023 (International)
  • THE HIGHEST NUMBER OF ONGOING CLINICAL TRIALS
    University Malaya Medical Centre, 2022 (University)
  • MK3475-585 : First Subject Randomized
    UMMC, 2020 (National)
  • High Performance for Study 237098; 8951-CL-0302-IMAB362 Gastric Cancer
    PAREXEL, 2019 (International)
  • Beaufort Middle School Outstanding Alumni Award
    Beaufort Middle School, 2019 (National)
  • Panel Pakar Penasihat Pihak Berkuasa Kawalan Dadah Bagi Tahun 2018
    Kementerian Kesihatan Malaysia, 2019 (Government)
  • Pencapaian Yang Cemerlang Dalam Kajian Percubaan Klinikal
    Jabatan Penyelidikan Klinikal (CIC) PPUM, 2019 (Department)
  • Achieving High Subject Recruitment in Malaysia for MK3475-394
    Merck Sharp & Dohme , 2019 (National)
  • Anugerah Perkhimatan Cemerlang Universiti Malaya
    Universiti Malaya, 2018 (University)
  • Standard Chartered KL Marathon 2018-Half Marathon (21.1KM) Malaysian Veteran
    Standard Chartered KL Marathon 2018, 2018 (International)
  • The 3rd Blue Cap Relay Run For Prostate Cancer 2017-2nd Runner Up, Cancer Survivors (3*3) Category
    Blue Cap Relay Run For Prostate Cancer , 2017 (National)
  • Managing Guest Editor for the Special Issue of Advances in Modern Oncology Research: "Progress of Cancer Research in Developing Countries" in 2017
    Advances in Modern Oncology Research, 2017 (International)
  • UM EXCELLENCE AWARD
    NAIB CANSELOR, 2015 (University)
  • University of Malaya Excellence Awards 2015 (ACUM 2015)- BOOK PUBLICATION
    University Malaya, 2015 (University)
  • TOP RECRUITER in South East Asia (Singapore, Malaysia, Vietnam) for OPTIMI1SE study Recruitment Challenge in Nov-Dec 2014
    Merck Serono & inVentiv Health clinical, 2014 (International)
  • Pertandingan Projek Pasukan Penambahbaikan Kualiti (QIT) 2014 Tempat Pertama
    Pusat sumber Kanser Payu Dara University Malaya, 2014 (International)
  • Spectrum 2.0+ Workshop
    Academic Development Center Univeristy of Malaya, 2013 (University)
  • Questionnaire validation workshop
    Julius Centre Univeristy of Malaya, 2013 (University)
  • Clinical Risk Management Workshop
    University Malaya Medical Centre, 2013 (University)
  • Problem Based Learning (PBL) Tutor Training Workshop for UMMP
    Medical Education and Research Development Unit, Faculty of Medicine, University Malaya., 2013 (University)
  • Credentialing & Privileging as a Consultant in Clinical Oncology, University Malaya Medical Centre.
    Medical Advisory Committee, 2013 (University)
  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2012 (University)
  • THE BREAST JOURNAL AWARDS
    36th Annual Symposium of the American Society of Breast Disease, 2012 (International)
  • Sijil Perkhidmatan Cemerlang, University Malaya
    University Malaya, 2011 (University)
  • Head & Neck Cancer-A Practical Approach to Radiological Anatomy Workshop
    Department of Radiotheraphy & Oncology,University Malaya Medical Center., 2010 (University)
  • Men's Uno Men of Substance Award
    Men's Uno Magazine, 2010 (National)
  • Honorable Mention Patient Management in recognition of the submission of the scientific abstract titled "Adjuvant Epirubicin, Cisplatin and Capecitabine (ECX) and Chemoradiation with Concurrent Capecitabine for Resected Gastric Cancer.
    7th Asia Pacific Oncology Summit, 2009 (International)
  • Outstanding Young Malaysians (Medical Innovation) Award
    JCI, 2009 (National)

PUBLICATIONS


Article in Journal
WoS
  1. Poh, Mau Ern; How, Soon Hin; Ho, Gwo Fuang; Pang, Yong Kek; Hasbullah, Harissa H.; Tho, Lye Mun; Nor, Ibtisam Muhamad; Lim, Bee Chiu; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Samsudin, Azlina; Omar, Azza; Ong, Choo Khoon; Soon, Sing Yang; Tan, Justin Yu Kuan; Abidin, Muhammad Adil Zainal (2023). Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country, CANCER MANAGEMENT AND RESEARCH. 15, 31-41. doi:10.2147/CMAR.S393729
  2. Ho, Gwo Fuang; Lee, Soo-Chin; Lim, Joanna; Bustam, Anita Zarina; Lim, Siew Eng; Saad, Marniza; Ow, Samuel Guan Wei; Ngoi, Natalie; Satar, Nur Fadhlina Abdul; Malik, Rozita Abdul; Alip, Adlinda; Law, Kian Boon; Toh, Yok Yong; Pan, Jia Wern; Teo, Soo Hwang (2022). A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR)., JOURNAL OF CLINICAL ONCOLOGY. 40(16)
  3. How, Soon Hin; Liam, Chong Kin; Abidin, Muhammad Adil Zainal; Hasbullah, Harissa H.; Tho, Lye Mun; Ho, Gwo Fuang; Nor, Ibtisam Muhamad; Pang, Yong Kek; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Ariffin, Roziana; Samsudin, Azlina; Omar, Azza; Tan, Sin Nee; Ong, Choo Khoon; Soon, Sing Yang; Poh, Mau Ern (2022). Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia, CANCER MANAGEMENT AND RESEARCH. 14, 1995-2005. doi:10.2147/CMAR.S364713
  4. How, Soon Hin; Tho, Lye Mun; Liam, Chong Kin; Hasbullah, Harissa H.; Ho, Gwo Fuang; Nor, Ibtisam Muhammad; Poh, Mau Ern; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Samsudin, Azlina; Omar, Azza; Ong, Choo Khoon; Pang, Yong Kek; Soon, Sing Yang (2022). Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country, THORACIC CANCER. . doi:10.1111/1759-7714.14442
  5. Lee, Lai Heng; Danchaivijitr, Pongwut; Uaprasert, Noppacharn; Gill, Harinder; Sacdalan, Dennis Lee; Ho, Gwo Fuang; Parakh, Rajiv; Pai, Paresh; Lee, Jen-Kuang; Rey, Nannette; Cohen, Alexander T. (2022). Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients, EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 11(1). doi:10.1186/s40164-022-00331-9
  6. Pivot, Xavier; Pegram, Mark D.; Cortes, Javier; Luftner, Diana; Lyman, Gary H.; Curigliano, Giuseppe; Bondarenko, Igor M.; Dvorkin, Mikhail; Ahn, Jin Hee; Im, Seock-Ah; Litwiniuk, Maria; Shparyk, Yaroslav V.; Ho, Gwo Fuang; Kislov, Nikolay V.; Wojtukiewicz, Marek; Sarosiek, Tomasz; Chae, Yee Soo; Ahn, Jin Seok; Jang, Hyerin; Kim, Sujung; Lee, Jiwon; Lee, Soo Young; Yoon, Ye Chan (2022). Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer, CANCER RESEARCH. 82(4). doi:10.1158/1538-7445.SABCS21-P2-13-04
  7. Qin, Shukui; Chen, Zhendong; Fang, Weijia; Ren, Zhenggang; Xu, Ruocai; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Ye, Xing; Ying, Jieer; Li, Jianfeng; Zhong, Wen Yan; Zhou, Yu; Siegel, Abby B.; Hao, Chunyi (2022). Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study, JOURNAL OF CLINICAL ONCOLOGY. 40(4). doi:10.1200/JCO.2022.40.4_suppl.383
  8. Wong, Li Ping; Lai, Lee Lee; See, Mee Hoong; Alias, Haridah; Omar, Sharifah Faridah Syed; Ng, Chong Guan; Ho, Gwo Fuang; Ong, Teng Aik; Wong, Yee Chi; Ooi, Po Lin; Elias, Jasmin Munchar; Hu, Zhijian; Lin, Yulan (2022). Adverse events following immunization and psychological distress among cancer patients/survivors following vaccination against SARS-CoV-2 infection, FRONTIERS IN PSYCHOLOGY. 13. doi:10.3389/fpsyg.2022.906067
Scopus
  1. Chan A.T.C., Lee V.H.F., Hong R.-L., Ahn M.-J., Chong W.Q., Kim S.-B., Ho G.F., Caguioa P.B., Ngamphaiboon N., Ho C., Aziz M.A.S.A., Ng Q.S., Yen C.-J., Soparattanapaisarn N., Ngan R.K.-C., Kho S.K., Tiambeng M.L.A., Yun T., Sriuranpong V., Algazi A.P., Cheng A., Massarelli E., Swaby R.F., Saraf S., Yuan J., Siu L.L. (2023). Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial, Annals of Oncology. 34(3), 251-261. doi:10.1016/j.annonc.2022.12.007
  2. Chopra S., Gupta A., Aoyama H., Wu H.-G., Mahmood H., Tharavichitkul E., Khine A., Gandhi A., Faruque G.M., Cruz M., Kodrat H., Xue X., Abeysinghe P., Ho G.F., Minjgee M., Tey J., Gao X. (2023). Radiation Oncology Research in Asia: Current Status and a Peep Into the Future From the Federation of Asian Organizations for Radiation Oncology, JCO global oncology. 9, e2300002. doi:10.1200/GO.23.00002
  3. Ho Y.Y., Hiew N.W.Y., Ho G.F. (2023). EXCEPTIONAL LONG-TERM SURVIVAL OF AN ELDERLY PATIENT WITH METASTATIC SMALL CELL NEUROENDOCRINE CARCINOMA OF THE CERVIX A CASE REPORT, Journal of Health and Translational Medicine. 26(2), 107-111. doi:10.22452/jummec.vol26no2.13
  4. Karajacob A.S., Azizan N.B., Al-Maleki A.R.M., Goh J.P.E., Loke M.F., Khor H.M., Ho G.F., Ponnampalavanar S., Tay S.T. (2023). Candida species and oral mycobiota of patients clinically diagnosed with oral thrush, PLoS ONE. 18(4 April). doi:10.1371/journal.pone.0284043
  5. Kuan W.-C., Kong Y.-C., Bustamam R.S., Wong L.-P., Woo Y.-L., Taib N.A., Ho G.-F., Zaharah H., Yip C.-H., Bhoo-Pathy N. (2023). Sexual Wellbeing and Supportive Care Needs After Cancer in a Multiethnic Asian Setting: A Qualitative Study, Sexuality and Disability. 41(1), 17-30. doi:10.1007/s11195-022-09772-w
  6. Ozguroglu M., Kilickap S., Sezer A., Gumus M., Bondarenko I., Gogishvili M., Nechaeva M., Schenker M., Cicin I., Ho G.F., Kulyaba Y., Zyuhal K., Scheusan R.-I., Garassino M.C., He X., Kaul M., Okoye E., Li Y., Li S., Pouliot J.-F., Seebach F., Lowy I., Gullo G., Rietschel P. (2023). First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial, The Lancet Oncology. 24(9), 989-1001. doi:10.1016/S1470-2045(23)00329-7
  7. Pivot X., Cortes J., Luftner D., Lyman G.H., Curigliano G., Bondarenko I.M., Ahn J.-H., Im S.-A., Litwiniuk M., Shparyk Y.V., Ho G.F., Kislov N.V., Wojtukiewicz M., Sarosiek T., Chae Y.S., Ahn J.S., Jang H., Kim S., Lee J., Yoon Y. (2023). Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial, JAMA Network Open. 6(4), E235822. doi:10.1001/jamanetworkopen.2023.5822
  8. Poh M.E., How S.H., Ho G.F., Pang Y.K., Hasbullah H.H., Tho L.M., Nor I.M., Lim B.C., Ho K.F., Thiagarajan M., Samsudin A., Omar A., Ong C.K., Soon S.Y., Tan J.Y.K., Abidin M.A.Z. (2023). Real-World Treatment and Outcomes of ALK-Positive Metastatic Non Small Cell Lung Cancer in a Southeast Asian Country, Cancer Management and Research. 15, 31-41. doi:10.2147/CMAR.S393729
  9. Qin S., Chen Z., Fang W., Ren Z., Xu R., Ryoo B.-Y., Meng Z., Bai Y., Chen X., Liu X., Xiao J., Ho G.F., Mao Y., Wang X., Ying J., Li J., Zhong W., Zhou Y., Siegel A.B., Hao C. (2023). Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial, Journal of Clinical Oncology. 41(7), 1434-1443. doi:10.1200/JCO.22.00620
  10. Yang T.-S., Chen H.-H., Bo-Wen L., Kim T.W., Kim J.G., Ahn J.B., Lee M.-A., Lin J., Ho G.F., Anh L.T., Temraz S., Burge M., Chua C., Huang J., Park Y.S. (2023). Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study, Asia-Pacific Journal of Clinical Oncology. . doi:10.1111/ajco.13920
  11. Ab Muin N.F., Ho G.F. (2022). THE RESPONSE TO ANAPLASTIC LYMPHOMA KINASE INHIBITOR IN METASTATIC ANAPLASTIC THYROID CARCINOMA., Brunei International Medical Journal. 2022(18), 84-88
  12. How S.H., Tho L.M., Liam C.K., Hasbullah H.H., Ho G.F., Muhammad Nor I., Poh M.E., Ho K.F., Thiagarajan M., Samsudin A., Omar A., Ong C.K., Pang Y.K., Soon S.Y. (2022). Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country, Thoracic Cancer. 13(11), 1676-1683. doi:10.1111/1759-7714.14442
  13. Yoon S.-Y., Wong S.W., Lim J., Ahmad S., Mariapun S., Padmanabhan H., Hassan N.T., Lau S.Y., Ch'ng G.-S., Haniffa M., Ong W.P., Rethanavelu K., Moey L.H., Keng W.T., Omar J., Mohd Abas M.N., Yong C.M., Ramasamy V., Md Noor M.R., Aliyas I., Lim M.C.K., Suberamaniam A., Mat Adenan N.A., Ahmad Z.A., Ho G.F., Abdul Malik R., Subramaniam S., Khoo B.P., Raja A., Chin Y.S., Sim W.W., Teh B.H., Kho S.K., Ong E.S.E., Voon P.J., Ismail G., Lee C.L., Abdullah B.Z., Loo K.S., Lim C.S., Lee S.J., Lim K.J.L., Shafiee M.N., Ismail F., Latiff Z.A., Ismail M.P., Mohamed Jamli M.F., Kumarasamy S., Leong K.W., Low J., Md Yusof M., Ahmad Mustafa A.M., Mat Ali N.H., Makanjang M., Tayib S., Cheah N., Lim B.K., Fong C.K., Foo Y.C., Mellor Abdullah M., Tan T.S., Chow D.S.Y., Ho K.F., Raman R., Radzi A., Deniel A., Teoh D.C.Y., Ang S.F., Joseph J.K., Ng P.H.O., Tho L.-M., Ahmad A.R., Muin I., Bleiker E., George A., Thong M.-K., Woo Y.L., Teo S.H. (2022). Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes, Journal of Medical Genetics. 59(3), 220-229. doi:10.1136/jmedgenet-2020-107416
Others
  1. Aravinthan Kadravello, Seng-Beng Tan , Gwo-Fuang Ho, Ranjit Kaur and Cheng-Har Yip. (2021). Exploring Unmet Needs from an Online Metastatic Breast Cancer Support Group: A Qualitative Study. Medicina 57(7):693. doi.org/10.3390/medicina57070693
  2. Chong E Von, Ho Gwo Fuang. (2021). A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. Respiratory Medicine Case Reports.Advance online publication.doi.org/10.1016/j.rmcr.2021.101478
  3. E. Von Cheong, Gwo Fuang Ho.(2021). Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma. Clinical Case Reports, 2021, 00-1-5.
  4. Ting Ting Tan , Maw Pin Tan , Chee Loong Lam, Ee Chin Loh , David Paul Capelle , Sheriza Izwa Zainuddin , Bin Ting Ang , Min Ai Lim , Natalie Zi Lai , Yu Zhen Tung , Hway Ann Yee , Chong Guan Ng, Gwo Fuang Ho, Mee Hoong See, Mei Sze Teh, Lee Lee Lai, Ranjit Kaur Pritam Singh, Chee Shee Chai, Diana Leh Ching Ng, Seng Beng Tan. (2021). Mindful gratitude journaling: psychological distress, quality of life and suffering in advanced cancer: a randomised controlled trial. BMJ Support Palliat Care. 2021 Jul 8;bmjspcare-2021-003068. doi: 10.1136/bmjspcare-2021-003068. Online ahead of print.
  5. Chai CS, Liam CK, Poh ME, Ong DBL, Pang YK, Cheah PL, Ho GF, Alip A. Predictors of acquired T790M mutation in patients failing first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer Management and Research 2020; 12:5439-5450
  6. Chew WZ, Jong WL, Jamaluddin Z, Fasha H, Kadri A, Mohamad A, Loh J and Ho GF. (2020). A Single institutional Audit of Setup errors for 3DCRT Rectal Cancers. JJournal of Health & Translational Medicine. 23(1), 6-10.
  7. Chin-Yang Song, Chin-Vern Song, Gwo-Fung Ho, Cheng-Har Yip. (2020). The role of radiogenomics in breast radiotherapy. Annals of Breast Surgery. doi:10.21037/abs.2019.12.01
  8. Dai Wee Lee, Gwo Fuang Ho. (2020). Palbociclib in the treatment of recurrent ovarian cancer. Gynecologic Oncology Reports, 34.
  9. Li-Ping Wong, Yek-Ching Kong, Nanthini Thevi Bhoo-Pathy, Shridevi Subramaniam, Ros Suzanna Bustamam, Nur Aishah Taib, Gwo-Fuang Ho, Hafizah Zaharah, Matin Mellor, Yin-Ling Woo, Cheng-Har Yip, Nirmala Bhoo-Pathy (2020.) Breaking News of Cancer Diagnosis: A Qualitative Study on the Experiences and Emotional Needs of Patients With Cancer in a Multiethnic Asian Setting. JCO Oncology Practice, doi: 10.1200/JOP.20.00002
  10. Yek-Ching Kong, Negina Rauf, Shridevi Subramaniam, Ros Suzanna Bustamam, Li-Ping Wong, Gwo-Fuang Ho, Hafizah Zaharah, Matin Mellor, Cheng-Har Yip, Nirmala Bhoo-Pathy. (2020). Working after cancer: in-depth perspectives from a setting with limited employment protection policies. Journal of Cancer Survivorship, DOI: 10.1007/s11764-020-00962-z
  11. Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo1,Raghav Sundar, Sing Huang Tan, Wei Peng Yon, Samuel G. W. Ow, Joline S. J. Lim1, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh and Soo-Chin Lee.(2020). A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer,20(1):1118.
  12. Ainhoa Costas-Chavarri, Govind Nandakumar, Sarah Temin, Gilberto Lopes, Andres Cervantes, Marcia Cruz Correa, Rena Engineer, Chisato Hamashima, Gwo Fuang Ho, et al. (2019). Treatment of Patients with Early-Stage Colorectal Cancer. Journal of Global Oncology, 5 (February 1 2019), 1-19.
  13. Gilberto Lopes, Mariana C. Stern, Sarah Temin, Ala I. Sharara, Andres Cervantes, Ainhoa Costas-Chavarri, Rena Engineer, Chisato Hamashima, Gwo Fuang Ho, et al (2019). Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline, Journal of Global Oncology, 5, (February 2019), 1-22.
  14. Jamalludin, Z., Jong, W. L., Ho, G. F., Rosenfeld, A. B., & Ung, N. M. (2019). In vivo dosimetry using MOSkin detector during Cobalt-60 high-dose-rate (HDR) brachytherapy of skin cancer. Australasian physical & engineering sciences in medicine, 1-9.
  15. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. (2019). Gwo-Fuang Ho,Chee-Shee Chai,Adlinda Alip, Mohd Ibrahim A. Wahid, Matin Mellor Abdullah,Yoke-Ching Foo, Soon-Hin How, Adel Zaatar, Kai-Seng Lam, Kin-Wah Leong, John-Seng-Hooi Low, Mastura Md Yusof,Erica Chai-Yong Lee,1Yok-Yong Toh, and Chong-Kin Liam. BMC Cancer,2019 (19), 896.
  16. Golkhalkhali B , Rajandram R , Paliany AS , Ho GF , Wan Ishak WZ , Johari CS , Chin KF.(2018). Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: A randomized controlled trial. Asia Pac J Clin Oncol. Asia Pac J Clin Oncol,14(3),179-191.
  17. K. Dhillon1, E. Tan, R. Akseer, Alhosani MS, Ho GF, Lim SHE,Jamaluddin ANSJ1. (2018). EMR Access and Confidentiality Based on Patient and Hospital Staff Perspectives.The Open Public Health Journal, 11.
  18. Lee DW and Ho GF. (2018). External auditory meatus involvement in nasopharyngeal carcinoma. Journal of Radiotherapy in Practice. page 1 of 3. doi: 10.1017/S1460396918000067
  19. Lee Lee Lai, Gwo Fuang Ho, Kin Fah Chin (2018). A case report on the use of self-expanding metallic stents in the treatment of stoma obstruction caused by advanced colonic cancer. Paripex-Indian Journal of Research, 7(1), 331-332.
  20. Rafid Salim Jabir, Gwo Fuang Ho, Muhammad Azrif,Johnson Stanslas (2018). Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients. Clinical Breast Cancer, May 2018.
  21. G. F. Ho, N. A. Taib, R. K. Pritam Singh, C. H. Yip, M. M. Abdullah, T. O. Lim. (2017). What If All Patients with Breast Cancer in Malaysia Have Access to the Best Available Care: How Many Deaths Are Avoidable? Global Journal of Health Science, 9(8).
  22. John Wen-Cheng Chang, Jun Guo, Chia-Yen Hung, Si Lu, Sang Joon Shin, Richard Quek, Anthont Ying, Gwo Fuang Ho, Huu Sau Hguyen, Boman Dhabhar, Virote Sriuranpong, Maria Luisa Tiambeng, Nugroho Prayogo, Naoya Yamazaki. (2017). Sunrise in melanoma management: Time to focus on melanoma burden in Asia. Asia-Pacific Journal of Clinical Oncology.
  23. Rafid Salim Jabir, Gwo Fuang Ho, Muhammad Azrif Bin Ahmad Annuar & Johnson Stanslas.(2017). Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients. Biomarkers.
  24. Andrew J Stewart Coats, Gwo Fuang Ho, Kumar Prabhash, Stephan Haehling, Julia Tilson, Richard Brown, John Beadle, Stefan D Anker. (2016) Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non small cell lung cancer or colorectal cancer: a randomized, double blind, placebo controlled, international multicentre phase II study (the ACT ONE trial). Journal of Cachexia, Sarcopenia and Muscle, 7 (3),355-365.
  25. Muthukkumaran Thiagarajan, Caryn Mei Hsien Chan, Ho Gwo Fuang, Tan Seng Beng, MA Atiliyana, NA Yahaya. (2016). Symptom Prevalence and Related Distress in Cancer Patients Undergoing Chemotherapy. Asian Pacific Journal of Cancer Prevention, 17(1),171-176.
  26. WL Jong, NM Ung, JHD Wong, KH Ng, WZ Wan Ishak, R Abdul Malik, VCE Phua, DL Cutajar, PE Metcalfe, AB Rosenfeld, GF Ho. (2016). In vivo skin dose measurement using MOSkin detectors in tangential breast radiotherapy. Physica Medica: European Journal of Medical Physics, 32(11), 1466-1474.
  27. A Wong, LZ Wang, FC Wong, S Ow, K Nesaretnam, A Pang, CS Tan, YW Lim, GF Ho, Y Lee, HL Yap, S Phang, AB Alip, KY Seng, BC Tai, R Walsh, BC Goh, SC Lee. 2015.Prospective, non-randomised, open-label study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy. European Journal of Cancer 51:S295-S296
  28. Abdullah BJJ, Yeong CH, Goh KL, Yoong BK, Ho GF, Carolyn Yim CW, Anajali K. Robotic Assisted Thermal Ablation of Liver Tumours. European Radiology. 2015. 25(1): 246-257
  29. Bhoo-Pathy N, Verkooijen HM, Wong FY, Pignol JP, Kwong A, Tan EY, Aishah Taib N, Nei WL, Ho GF, Tan B, Chan P, Lee SC, Hartman M, Yip CH, Dent R. (2015). Prognostic role of adjuvant radiotherapy in triple negative breast cancer: a historical cohort study. Int J Cancer,137(10), 2504-12.
  30. C.M.H. Chan, W.A. Wan Ahmad, M. Md Yusof,G.F. Ho and E. Krupat. 2015.Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer. European Journal of Cancer Care 24(6):938 944.
  31. GF Ho, MY Mastura, RP Kaur, LP Hoo, TO Lim. 2015. P0170 Trastuzumab for HER2-positive breast cancer: Experience from a middle-income Asian country. European Journal of Cancer 51(S2):e32-e33
  32. Jaslyn Sian-Siu Soo , Char-Hong Ng , Si Hoey Tan, Rozita Abdul Malik, Yew-Ching Teh, Boon-Shing Tan, Gwo-Fuang Ho, Mee-Hoong See, Nur Aishah Mohd Taib, Cheng-Har Yip, Felicia Fei-Lei Chung, Ling-Wei Hii, Soo-Hwang Teo , Chee-Onn Leong. 2015. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. Apoptosis 20 (10): 1373-1387
  33. Jieping Lei, Anja Rudolph, Kirsten B Moysich, Sajjad Rafiq, Sabine Behrens, Ellen L Goode, Paul PD Pharoah, Petra Seibold, Peter A Fasching, Irene L Andrulis, Vessela N Kristensen, Fergus J Couch, Ute Hamann, Maartje J Hooning, Heli Nevanlinna, Ursula Eilber, Manjeet K Bolla, Joe Dennis, Qin Wang, Annika Lindblom, Arto Mannermaa, Diether Lambrechts, Montserrat Garc a-Closas, Per Hall, Georgia Chenevix-Trench, Mitul Shah, Robert Luben, Lothar Haeberle, Arif B Ekici, Matthias W Beckmann, Julia A Knight, Gord Glendon, Sandrine Tchatchou, Grethe I Grenaker Aln s, Anne-Lise Borresen-Dale, Silje Nord, Janet E Olson, Emily Hallberg, Celine Vachon, Diana Torres, Hans-Ulrich Ulmer, Thomas R diger, Agnes Jager, Carolien HM van Deurzen, Madeleine MA Tilanus-Linthorst, Taru A Muranen, Kristiina Aittom ki, Carl Blomqvist, Sara Margolin, Veli-Matti Kosma, Jaana M Hartikainen, Vesa Kataja, Sigrid Hatse, Hans Wildiers, Ann Smeets, Jonine Figueroa, Stephen J Chanock, Jolanta Lissowska, Jingmei Li, Keith Humphreys, Kelly-Anne Phillips, kConFab Investigators, Sabine Linn, Sten Cornelissen, Sandra Alexandra J van den Broek, Daehee Kang, Ji-Yeob Choi, Sue K Park, Keun-Young Yoo, Chia-Ni Hsiung, Pei-Ei Wu, Ming-Feng Hou, Chen-Yang Shen, Soo Hwang Teo, Nur Aishah Mohd Taib, Cheng Har Yip, Gwo Fuang Ho, Keitaro Matsuo, Hidemi Ito, Hiroji Iwata, Kazuo Tajima, Alison M Dunning, Javier Benitez, Kamila Czene, Lara E Sucheston, Tom Maishman, William J Tapper, Diana Eccles, Douglas F Easton, Marjanka K Schmidt, and Jenny Chang-Claude. 2015.Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.Breast Cancer Res 17(1): 18.
  34. Puvaneswari Meganathan, Rafid Salim Jabir, Ho Gwo Fuang, Nirmala Bhoo-Pathy, Roma Basu Choudhury, Nur Aishah Taib, Kalanithi Nesaretnam & Zamri Chik.2015.A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects.Scientific Reports.Scientific Reports 5, Article number: 13550
  35. Subramaniam S, Bhoo-Pathy N, Taib NA, Tan GH, See MH, Jamaris S, Ho GF, Looi LM, Yip CH. (2015) .Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.World J Surg. 2015 Jul 3. [Epub ahead of print]
  36. WH Tang, GF Ho, M Saad, NA Taib, MH See, P Liau, MI Wahid, LM Tho.2015.Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country. European Journal of Cancer 51(S3):S276-S277
  37. Wong HS1, Subramaniam S, Alias Z, Taib NA, Ho GF, Ng CH, Yip CH, Verkooijen HM, Hartman M, Bhoo-Pathy N.2015.The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer.Medicine (Baltimore) 94(8):e593.
  38. Ann-Lii Cheng, Jin Li, Ashok K. Vaid, Brigette Buig Yue Ma, Catherine Teh, Joong B. Ahn, Maximino Bello, Chaiyut Charoentum, Li-Tzong Chen, Gilberto de Lima Lopes, Jr. Gwo. F Ho, Hwai L. Kong, Ka O. Lam, Tian S. Liu, Young S. Park, Virote Sriuranpong, Aru W. Sudoyo, Jaw-Yuan Wang, Jun Zhang, Su Z. Zhang, Fortunato Ciardiello, Clause-Henning Kohne, Michael Shaw, Tae Won Kim. 2014. Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consenses.Clinical Colorectal Cancer 13(3):145-155
  39. Basri Johan Jeet Abdullah,Chai Hong Yeong,Khean Lee Goh,Boon Koon Yoong,Gwo Fuang Ho,Carolyn Chue Wai Yim,Anjali Kulkarni.2014. Robot-assisted radiofrequency ablation of primary and secondary liver tumours: early experience. European Radiology 24(1):79-85.
  40. Caryn Mei Hsien Chan, Wan Azman Wan Ahmad, Mastura Md Yusof, Gwo-Fuang Ho, Edward Krupat. Effects of depression and anxiety on mortality in a mixed cancer group: a longitudinal approach using standardised diagnostic interviews.Psycho-oncology, 2014 October 23.
  41. Char-Hong Ng, Nirmala Bhoo Pathy, Nur Aishah Taib, Gwo- Fuang Ho, Kein-Seong Mun, Anthony Rhodes, Lai- Meng Looi, Cheng-Har Yip.2014. Do Clinical Features and Survival of Single Hormone Receptor Positive Breast Cancers Differ from Double Hormone Receptor Positive Breast Cancers? Asian Pac J Cancer Prev 15(18): 7959-7964.
  42. Hashim N, Jamaluddin Z, Ung NM, Ho GF, Malik RA, Phua VCE, 2014. CT-based 3-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: comparison between dose-volume histograms and ICRU point doses of the rectum and bladder. Asian Pacific J Cancer Prev, 15 (13), 5259-5264
  43. Jingmei Li,Linda S. Lindstr m,Jia N. Foo,Marjanka K. Schmidt,Paul D. P. Pharoah,Kyriaki Michailidou,Manjeet K. Bolla,Qin Wang,Laura J. Van t Veer,Sten Cornelissen,Emiel Rutgers, Melissa C. Southey,Carmel Apicella,Gillian S. Dite,John L. Hopper,Peter A. Fasching,Lothar Haeberle,Arif B. Ekici,Matthias W. Beckmann,Carl Blomqvist,Taru A. Muranen,Kristiina Aittom , Annika Lindblom,Sara Margolin,Arto Mannermaa,Veli-Matti Kosma,Jaana M. Hartikainen,Vesa Kataja,Georgia Chenevix-Trench,kConFab Investigators,Kelly-Anne Phillips,Sue-Anne McLachlan, Diether Lambrechts,Bernard Thienpont,Ann Smeets,Hans Wildiers,Jenny Chang-Claude,Dieter Flesch-Janys,Petra Seibold,Anja Rudolph,Graham G. Giles,Laura Baglietto,Gianluca Severi, Christopher A. Haiman,Brian E. Henderson,Fredrick Schumacher,Loic Le Marchand,Vessela Kristensen,Grethe I. Grenaker Aln Anne-Lise Borresen-Dale,Silje Nord,Robert Winqvist, Katri Pylk Arja Jukkola-Vuorinen,Mervi Grip,Irene L. Andrulis,Julia A. Knight,Gord Glendon,Sandrine Tchatchou,Peter Devilee,Robert Tollenaar,Caroline Seynaeve,Maartje Hooning, Mieke Kriege,Antoinette Hollestelle,Ans van den Ouweland,Yi Li,Ute Hamann,Diana Torres,Hans U. Ulmer,Thomas R diger,Chen-Yang Shen,Chia-Ni Hsiung,Pei-Ei Wu,Shou-Tung Chen, Soo Hwang Teo,Nur Aishah Mohd Taib,Cheng Har Yip,Gwo Fuang Ho,Keitaro Matsuo,Hidemi Ito,Hiroji Iwata,Kazuo Tajima,Daehee Kang,Ji-Yeob Choi,Sue K. Park,Keun-Young Yoo,Tom Maishman, William J. Tapper,Alison Dunning,Mitul Shah,Robert Luben,Judith Brown,Chiea Chuen Khor,Diana M. Eccles,Heli Nevanlinna,Douglas Easton,Keith Humphreys,Jianjun Liu,Per Hall & Kamila Czene. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy.Nature Communications 5: 4051
  44. Lim G.C., Aina E.N., Cheah S.K., Ismail F, Ho G.F., Tho L.M., Yip C.H., Taib N.A., Chong K.J., Dharmaratnam J., Abdullah M.M., Mohamed A.K., Ho K.F., Ratnavelu K, Lim K.M.,Leong K.W., Wahid I.A., Lim T.O.2014.Closing the global cancer divide- performance of breast cancer care services in a middle income developing country.BMC Cancer 14 :212
  45. M.Y. Mastura, S. MARNIZA, W.I. Wan Zamaniah, P. Vincent, A.M. Rozita, A. Adlinda, G.F. Ho. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series. European Journal of Cancer 05/2014; 50:e48-e49.
  46. Swee Sung Soon, Whay-Kuang Chia, Mun-Ling Sarah Chan, Gwo Fuang Ho, Xiao Jian, Yan Hong Deng, Chuen-Seng Tan, Atul Sharma, Eva Segelov, Shaesta Mehta, Raghib Ali, Han-CHong Toh. Hwee-Lin Wee. 2014. Cost- Effectiveness of Aspirin Adjuvant Therapy in Early Stage Colorectal Cancer in Older Patients. PLos ONE 9 (9):e107866
  47. Wei Loong Jong, Jeannie Hsiu Ding Wong, Ngie Min Ung, Kwan Hoong Ng, Gwo Fuang Ho, Dean L. Cutajar, Anatoly B. Rosenfeld. 2014. Characterization of MOSkin detector for in vivo skin dose measurement during megavoltage radiotherapy. Journal of Applied Clinical Medical Physics, 15(5):120-132
  48. Z.K. Zaman, N.M. Ung, R.A. Malik, G.F. Ho, V.C.E. Phua, Z. Jamalludin, M.T.H. Baharuldin, K.H. Ng. 2014. Comparison of planned and measured rectal dose in-vivo during high dose rate Cobalt-60 brachytherapy of cervical cancer. Physica Medica.
  49. G.C.C. Lim, N.A. Emran, G.W. Ho, C.H. Yip, K.J. Chong, M.M. Abdullah, A.K. Mohamed, Y.C. Foo, K.F. Ho, R. Kananathan, K.W. Leong, I.A. Wahid, T.O. Lim.2013.Closing the Cancer Divide: Performance of Breast Cancer Care in the middle income country Malaysia.European Journal of Cancer(49):S1
  50. BMJ Open. 2012 Oct 3;2(5). pii: e001799. doi: 10.1136/bmjopen-2012-001799. Print 2012. Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: a prospective study protocol. Mei Hsien CC, Wan Azman WA, Md Yusof M, Ho GF, Krupat E.
  51. Bhoo-Pathy, N.; Yip, C.H.; Hartman, M.; Saxena, N.; Taib, N.A.; Ho, G.F.; Looi, L.M.; Bulgiba, A.M.; van der Graaf, Y.; Verkooijen, H.M. (2012) Adjuvant! online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer, 48 (7). pp. 982-9. ISSN 1879-0852
  52. Rafid Salim Jabir, Rakesh Naidu, Muhammad Azrif Bin Ahmad Annuar,Gwo Fuang Ho, Murali Munisamy, Johnson Stanslas. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics (2012) 13(16), 1979 1988. ISSN 1462-2416
  53. Tho LM, McJury M, Ho GF, Han S, Muirhead R Challenges in the delivery of radical radiotherapy for locally advanced non-small cell lung cancer. Biomed Imaging Interv J 2012; 8(3):e20
  54. Andrew J Stewart Coats, Venkatesan Srinivasan, Jayaraman Surendran, Haritha Chiramana, Shankar R K G Vangipuram, Nirajkumar N Bhatt, Minish Jain, Sandip Shah, Irfhan A B H Ali, Ho G Fuang, Mohammed Z M Hassan, John Beadle, Julia Tilson, Bridget-Anne Kirwan, Stefan D Anker The ACT-ONE trial, a multicentre, randomised, double-blind, placebo- controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non- small cell lung cancer and colorectal cancer: study design. Journal of cachexia, sarcopenia and muscle 12/2011; 2(4):201-207. DOI:10.1007/s13539-011-0046-2
  55. Raghib Ali1 , Han-Chong Toh2 and Whay-Kuang Chia2* , The ASCOLT trial investigators The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer - The ASCOLT study: Study Protocol for a randomized controlled trial. Ali et al. Trials 2011, 12:261 http://www.trialsjournal.com/content/12/1/261
  56. HO G F, CHAPPELL M, ROBINSON A. Invasive lobular carcinoma of the breast diagnosed from an ovarian tumour. Malaysian J Pathol 2008;30(2):121 124.
Books
  1. Dr. Ho Gwo Fuang. 2015. Cancer and You. Malaysia: Mentor Publishing Sdn. Bhd.
  2. Ho Gwo Fuang.2014.Written for Cancer Patient. Malaysia:Mentor Publishing Sdn Bhd.
Article in Proceeding
  1. Anthony T. C. Chan; Victor Ho Fun Lee; Ruey-Long Hong; Myung-Ju Ahn; Wan Qin Chong; Anna Spreafico; Sung-Bae Kim; Gwo Fuang Ho; Priscilla B. Caguioa; Nuttapong Ngamphaiboon; Ramona F. Swaby; Bo Wei; Andrea Webber; John Kang; Burak Gumuscu; Jianda Yuan; Lillian Siu. (2023). Abstract PO-008: Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122. Clinical Cancer Research, 29 (18_Supplement): PO-008. https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-008
  2. G.F. Ho, S.C. Lee, J.W. Pan, A.Z. Bustam, A. Alip, N.F. Bt Abdul Satar, M. Saad, R. Abdul Malik, S.E. Lim, S. Ow, N.Y.L. Ngoi, K.B. Law, Y.Y. Toh, B. Selvam, J. Lim, S-H. Teo. (2023). A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR). Annals of Oncology, 34, SUPPLEMENT 4 (S1486). DOI:https://doi.org/10.1016/j.annonc.2023.10.188
  3. J.W.K. Chia, E. Segelov, Y. Deng, W. Wang, G.F. Ho, A. Sharma, K. Ding, G. Chen, G.M. Jeffery, L.M. Nott, R. Zielinski, J.B. Ahn, T-Y. Chao, T. Yau S. Nabilah, M. Gandhi, P. Rothwell, J. Simes, R. Ali, H.C. Toh. (2023). Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial. Annals of Oncology, 34, SUPPLEMENT 2 (S1269). DOI:https://doi.org/10.1016/j.annonc.2023.10.021
  4. L. Wu, J. Li, C. Xu, B. Biswas, K. Tang, H. Wang, Z. Liu, U. Batra, G.F. Ho, S.H.J. Low, Y. Lu, M. Zhao, L.M. Tho, J. Zhao, S. He, J. Huang, X. Tang, C.H. Wong, Y-L. Wu. (2023)Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study. Annals of Oncology, 34, SUPPLEMENT 2 (S771). DOI:https://doi.org/10.1016/j.annonc.2023.09.2370
  5. Yun Yi Ho, Nia Wei Yuen Hiew, Gwo Fuang Ho., (2022, Nov) Exceptional Long-term Survival of an Elderly Patient with Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix A Case Report. [Paper presentation]. 33rd Annual Scientific Congress of Malaysian Oncological Society 2022, Kuala Lumpur, Malaysia.
  6. Lee WC, Ho GF. Extended-field irradiation (EFRT) and intra-cavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic lymph nodes. Abstract and poster for Asian Oncology Summit 2009, Singapore.
  7. Rejab M, Wong DWY, Zamzarinah K, Saad M, Bustam A, Ho G. Computerized versus Conventional Planning for Craniospinal Irradiation of Medulloblastoma A Dosimetric Study .
  8. Zamzarinah KZ, Ho G, Wong DWY, Taufik Hidayat M, Ng KH. Conformal radiotherapy to large breast using segmented fields . Poster in Asia-Oceania Congress of Medical Physics & South-East Asian Congress of Medical Physics, Ho Chi Minh City, Vietnam, October 2008
  9. Ho G, Mair G, Oliver T et al Long term outcome of chemoradiation to bladder cancer using MOPq10 regime . Abstract and poster in National Cancer Research Institute (NCRI) meeting, Birmingham, Oct 2005.
  10. Ho G, Bridgewater C, Powell M. Chemoradiotherapy for locally advanced head and neck cancer using weekly cisplatin Abstract in British Journal of Cancer, June 2003. Presented in British Cancer Research Meeting, Bournemouth, 5 June 2003
Other Publications
  1. Bhoo-Pathy, N.; Kong, Y. C.; Bustamam, R. S.; Bin, A. Matin Mellor; Zaharah, H.; Taib, N. A.; Ho, G. F.; Yip, C. H. (2019). Needs of cancer patients in an Asian setting. Annals of Oncology (30) Supplement 9, ix141. - Extended Abstract
  2. Chai, C. S.; Liam, C. K.; Lin, O. Po; Pang, Y. K.; Ho, G. F.; Alip, A.; Wong, C. K.; Poh, M. E.; Tan, J. L. (2019). Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma. Annals of Oncology, 30 (Supplement_9). - Extended Abstract
  3. Chai, C. S.; Lin, O. Po; Liam, C. K.; Pang, Y. K.; Ho, G. F.; Alip, A.; Wong, C. K.; Poh, M. E.; Tan, J. L. (2019). Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib. Annals of Oncology 30 (Supplement_9) - Extended Abstract
  4. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Chan Ahn Y, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. (2019). Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer. Journal of Thoracic Oncology, online publication. doi: 10.1016/j.jtho.2019.10.022. - Extended Abstract
  5. Tan, A. C.,Loong, H.,Ho, G. F., Seet, A.,Chiam, B.;Cheah, D. Q.,Tan, G. S.,Lim, K. H.,Yang, J. C-H.,Mok, T. S. K.,Kim, D-W.,Tan, D. S. W. (2019).Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001). Annals of Oncology 30 (Supplement_9). - Extended Abstract
  6. Robert John Walsh, Soo Chin Lee, Kok Yong Seng, Ling-Zhi Wang, Gwo Fuang Ho, Samuel Guan Wei Ow, Nesaretnam Barr Kumarakulasinghe, Raghav Sundar, Xiao Wen Lee, Hui-Ling Yap, Anand Devaprasath Jeyasekharan, Angela Pang, Jingshan Ho, Chee Seng Tan, Yi Wan Lim, Rozita Abdul Malik, Wan Zamaniah Wan Ishak, Boon Cher Goh, Bee Choo Tai, Andrea Li Ann Wong (2017). Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. Journal of Clinical Oncology, 35(15) suppl (May 2017) 1056-1056. - Extended Abstract
  7. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Center: Psychological Factors to face Cancer:Anxiety. Health Quotient Magazines. Dec 2014 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  8. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Center: Psychological Factors to face Cancer:Anger. Health Quotient Magazines. March 2014 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  9. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Center: Psychological Factors to face Cancer: Depress. Health Quotient Magazines. September 2014 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  10. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Center: Psychological Factors to face Cancer. Health Quotient Magazines. March 2014 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  11. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Health Perservation VS Cure Disease.Sin Chew Daily Plus 16th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  12. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Introduction of Radiotherapy.Sin Chew Daily Plus 20th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  13. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Metastatic Brain Tumor.Sin Chew Daily Plus 21th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  14. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Prevention of Cancer I.Sin Chew Daily Plus 28th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  15. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Sabah Snake Grass--A good treatment for cancer? Sin Chew Daily Plus 23th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  16. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Stereotactic Radiosurgery.Sin Chew Daily Plus 17th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  17. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Treatment of Testicular Cancers.Sin Chew Daily Plus 13th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  18. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Drug Therapy.Sin Chew Daily Plus 24th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  19. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Local Treatment of Carcinoma.Sin Chew Daily Plus 15th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  20. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Prevention of Cancer II.Sin Chew Daily Plus 29th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  21. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Screening and Testing of Cancer.Sin Chew Daily Plus 27th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  22. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Treatment of Lung Carcinoma.Sin Chew Daily Plus 22th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  23. Dr Ho Gwo Fuang,Clinical Oncology Unit,University Malaya Medical Centre:Treatment of Colorectal Carcinoma.Sin Chew Daily Plus 14th May 2013 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  24. Ng Char Hong, MD; Nirmala Bhoo-Pathy, MD; NurAishah Taib, MD; Ho Gwo-Fuang, MD; Anthony Rhodes, MD; Yip Cheng-Har, MD,2012.Do Clinical Features and Survival of Single Hormone Positive Breast Cancers Differ from Double Positive Hormonal Breast Cancers? 36th Annual Symposium of the American Society of Breast Disease,THE BREAST JOURNAL AWARDS. - Extended Abstract
  25. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:The important of Daily Diet.Sin Chew Daily Plus 25th Mar 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  26. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Prevention of Cancers.Sin Chew Daily Plus 15th Apr 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  27. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Subsequent Treatment must be based on the Logic of Science.Sin Chew Daily Plus 18th Mar 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  28. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Targeted Therapy For Cancers.Sin Chew Daily Plus 1st Apr 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  29. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Continuous Treatment to Prevent Relapse of Breast Cancer.Sin Chew Daily Plus 04th Mar 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  30. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Everyone has Cancer? Sin Chew Daily Plus 08th Apr 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  31. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:My Tzu Chi Trip 1.Sin Chew Daily Plus 7th Nov 2011-12th Nov 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  32. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:My Tzu Chi Trip 4.Sin Chew Daily Plus 7th Nov 2011-12th Nov 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  33. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:My Tzu Chi Trip 5.Sin Chew Daily Plus 7th Nov 2011-12th Nov 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  34. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:My Tzu Chi Trip 6.Sin Chew Daily Plus 7th Nov 2011-12th Nov 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  35. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:The Patient Brave Participation becomes Power in Cancer Research.Sin Chew Daily Plus 18th Mar 2011 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  36. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Nasopharyngeal Cancers.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  37. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Brain Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  38. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Breast Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  39. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Cancer Complications.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  40. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Cevical Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  41. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Colorectal Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  42. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Gastric Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  43. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Kidney Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  44. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Liver Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  45. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Lung Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  46. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Lymphoma.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  47. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Ovarian Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  48. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:3 Minutes to know Prostate Cancer.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  49. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Don't Panic, Surgery NOT a Must.Sin Chew Daily Plus 15th Apr 2010-5th May 2010 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  50. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:Advancing cancer in the prostate.The Star 1st March 2009 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  51. Dr Ho Gwo Fuang,Clinical Oncology Unit, University Malaya Medical Centre:The Silent Killer.The Star 30th Aug 2009 - Mass Media(Newspaper,Radio,Tv,Popular Magazine)
  52. Ho G, Popat S, Nutting C. Induction and concurrent chemoradiotherapy for non-small cell lung cancer (NSCLC) using cisplatin and vinorelbine . Abstract in Lung Cancer, Volume 60, Supplement 1, April 2008, Page S18. - Extended Abstract
  53. Rosenfelder N, Wolstenholme V, Ho G, Tait D, Hawkins M et al Interobserver Concordance for Computed Tomography Target Volume Delineation for Breast Electron Boost Radiotherapy . Abstract and poster in European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, G teborg (Sweden), Sep 2008. - Extended Abstract
  54. Ho G, Jakowska P, Teoh M, Harrington K et al Dosimetric problems in radiotherapy for bilateral parotid gland acinic cell carcinomas . Abstract and poster in UKRO meeting, Edinburgh, April 2007. - Extended Abstract
  55. Ho G, Rostom A. Impact of FDG-PET scan on the staging and management of patients with breast cancer . Abstract in Clinical Oncology 19(4): S3, May 2007. Oral presentation in Royal College of Radiologists Annual Scientific Meeting Sep 2006 - Extended Abstract
  56. 4)Sharp M, Vilarino-Varela M, Ho G, Plowman P et al Virtual Simulation for Wilms Tumour . Abstract in Clinical Oncology 17(2): S29 P33. Poster in UKRO, York, March 2005. - Extended Abstract
  57. Ho G, Sharp M, Vilarino-Varela M, Plowman P et al Isodosimetric Problems in Neuraxis Radiotherapy for Very Large Patients . Abstract in Clinical Oncology 17(2):S31 P44, April 2005. Poster in UK Radiation Oncology meeting, York, March 2005 - Extended Abstract
  58. Vilarino-Varela M, Ho G, Plowman P et al Targeting Single Orbital Muscles with Stereotactic Radiotherapy . Abstract in Clinical Oncology 17(2): S39 P83. Poster in UKRO, York, March 2005 - Extended Abstract

RESEARCH PROJECT


National
  1. 2013 - 2019, NONE
    Observational Prospective Study in Management of 1st line KRAS Wildtype mCRC with Erbitux (Cetuximab)-OPTIM1SE ( Principal Investigator(PI))
  2. 2014 - 2018, Roche
    A RANDOMIZED, MULTICENTRED. OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTAMSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE PROGRESSIVE OR RECURRENT LOCALLY ADVANCED OR METASTATIC BREAST CANCER ( Consultant)
  3. 2016 - 2018, Educational grant
    Retrospective analysis of patients with EGFR mutation positive lung cancer treated with Afatinib in Malaysia ( Principal Investigator(PI))
  4. 2012 - 2017, Quintiles Janseen Cilaq
    ABI-PRO- 3002 A phase 3, randamized, double-blind,placebo-controlled study of abiraterone acetate)JNJ-212082) plus prednisone in asymtomic ormildly symptomatic patients with metastaticcastration-resistant prostate cancer ( Consultant)
  5. 2013 - 2017, Roche
    YO28322(MetGastric Study) A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy and Safety of Onartuzumab (MetMAb) in Combination with 5-Fluorocil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients with Metastatic HER2-Negative, Met-Positive Gastroesophageal Cancer ( Consultant)
  6. 2014 - 2017, AB SCIENCE
    A Prospective, Multicentre, Randomized, Double Blind, Placebo-Controlled, 2-Parallel Groups, Phase 3 Study in Combination to Compare The Efficacy and Safety of (Masitinib in Combination With Irinotecan, 50fluorouracil and Folinic Acid (FOLFIRI) to Placebo (Placebo In Combination With FOLFIRI) in Second Line Treatment of Patients With Metastaic Colorectal Cancer. ( Principal Investigator(PI))
  7. 2016 - 2017, Private Funding
    A Phase III, Randomized, Open-Label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progresses after First-Line Therapy with Platinum and Fluoropyrimidine ( Consultant)
  8. 2015 - 2017, Private Funding
    MONALEESA 7 BREAST CANCER STUDY ( Consultant)
  9. 2012 - 2015, Roche
    B027952 (GATSBY Study) A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treated locally advanced or metastatic HER2-positive gastric cancer, including adenocarcinoma of the gastroesophageal function. ( Consultant)
  10. 2013 - 2015, NONE
    Phase II randomized study of docetaxel with or without low-dose, short course sunitinib in the treatment of advanced solid tumors. ( Principal Investigator(PI))
  11. 2011 - 2013, Janssen Cilag
    An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy ( Consultant)
  12. 2011 - 2013, High Impact Research (HIR)
    Lapatinib study Phase II open-labelstudy of preoperativeweeklypac55 litaxel and carboplatinwithlapatinib (Tykerb ) in patientswith ErB2-positive stage I-III Breastc ncer ( Principal Investigator(PI))
  13. 2011 - 2012, High Impact Research (HIR)
    Clinical and Biological Effects of Metformin in combination with Chemotherapy (FEC) in Locally Advanced Breast Cancer in Malaysia - a pilot study ( Consultant)
  14. 2008 - 2012, Wyeth
    An international multi-centre phase III randomised controlled trial of first line treatment of advanced renal cell carcinoma, comparing bevacizumab + interferon-alpha versus bevacizumab + torisel. ( Consultant)
  15. 2008 - 2012, Geran Penyelidikan Universiti Malaya (UMRG)
    Induction and concurrent chemoradiation with cetuximab for treatment of locally advanced Nasopharyngeal Carcinoma ( Principal Investigator(PI))
  16. 2010 - 2012, Fundamental Research Grant Scheme (FRGS)
    Pharmacokinetics and pharmacogenomics of docetaxel in adjuvant breast cancer. ( Consultant)
  17. 2008 - 2011, Cancer Research Centre, Ministry of Health, Malaysia
    NPC Study An open labeled, multicentre, randomized phase II trial of combination gemcitabine and carboplatin chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma. ( Principal Investigator(PI))
  18. 2008 - 2010, Short Term Research Fund (Vote F)(PJP)
    A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study) ( Consultant)
International
  1. 2010 - 2026, NCC Singapore
    ASCOLT Aspirin in treating patients with Dukes stage C colon or rectal cancer, or high risk Dukes stage B colon cancer that has been completely removed by surgery. ( Principal Investigator(PI))
  2. 2019 - 2024, celltrion
    A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer ( Consultant)
  3. 2019 - 2024, Private Funding
    A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastrosophageal Junction (GEJ) Adenocarcinoma. ( Consultant)
  4. 2020 - 2024, Private Funding
    A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585) ( Principal Investigator(PI))
  5. 2019 - 2023, International Funding
    A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1) Antibody and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer ( Principal Investigator(PI))
  6. 2019 - 2021, MSD LTD
    MK3475-966 Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for FirstLine Advanced and/or Unresectable Biliary Tract Carcinoma (KEYNOTE-966) ( Consultant)
  7. 2014 - 2019, Zeria Pharmaceutical Co., Ltd
    Randomized, Double-blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer A Phase III trial ( Consultant)
  8. 2017 - 2019, Private Funding
    A Phase III, Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394) ( Principal Investigator(PI))
  9. 2017 - 2019, Private Funding
    A Two-Part Phase 2/3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus mFOLFOX6 Versus Placebo Plus mFOLFOX6 in Subjects with HER1/HER2 Co-Expressing Advanced or Metastatic Gastric Cancer Without Prior Exposure to Systemic Therapy ( Principal Investigator(PI))
  10. 2017 - 2019, Private Funding
    A Randomized, Multicenter, Double-blind, Placebo-Controlled, Phase 3 study of Weekly Paclitaxel with or without Ramucirumab (IMC-1121B) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive after First-Line Therapy with Platinum and Fluoropyrimidine. ( Principal Investigator(PI))
  11. 2016 - 2018, Private Funding
    A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122) ( Principal Investigator(PI))
  12. 2010 - 2016, Pfizer
    Phase 3 open label first line treatment for HER2 positive breast cancer comparing Paclitaxel plus herceptin vs Paclitaxel plus Neratinib. ( Consultant)
  13. 2014 - 2016, Samsung Bioepis
    A Phase III Randomised, Double-Blind,Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting ( Principal Investigator(PI))
  14. 2014 - 2015, Genetech Inc
    GDC-0068 Study (JAGUAR) A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, An Inhibitor to Akt, In Combination with Fluoropyrimidine plus Oxaliplatin in Patients with Locally Advanced or Mestatatic Gastric or Gastroesophageal Junction Adenocarcinoma ( Consultant)
  15. 2014 - 2015, NUS
    A Prospective Cohort Study of Patients with Malignant Cord Compression ( Consultant)
  16. 2012 - 2014, GENETECH INC
    A Phase II double-blind placebo-controlled randomised study of GDC-0941 or GDC-0980 with fulvestrant versus fulvestrant in metastatic breast cancer patients resistant to aromatase inhibitors. ( Consultant)
  17. 2011 - 2013, AMGEN COOPERATION
    A PHASE 3, MULTICENTRE, RANDOMIZED, OPEN LABEL TRIAL TO EVALUATE THE SURVIVAL BENEFIT OF PANITUMUMAB AND BEST SUPPORTIVE CARE, COMPARED TO BEST SUPPORTIVE CARE ALONE, IN SUBJECT WITH CHEMOREFRACTORY WILD-TYPE KRAS METASTATIC COLORECTAL CANCER ( Consultant)
  18. 2011 - 2013, Psioxus Therapeutic Limited
    MT-102-2001 : (Myotec Study) A multicentre, randomized, double-blind, placebo- controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non small-cell lung cancer and colorectal cancer. ( Principal Investigator(PI))
  19. 2009 - 2012, Boehringer-Ingelheim
    LUME-Lung 2 An international, multi-centre phase III randomised controlled trial for second line treatment of recurrent, advanced non-small cell lung cancer, comparing pemetrexed + placebo versus pemetrexed + BIBF1120 (a multi-targeted tyrosine kinase inhibitor). ( Consultant)
  20. 2010 - 2012, Amgen
    ASPECCT Panitumumab vs cetuximab for the third line treatment of advanced colorectal cancer. ( Principal Investigator(PI))
  21. 2008 - 2011, Pfizer
    A multinational, randomised, open-label, phase 3 study of sunitinib malate vs sorafenib in patients with advanced hepatocellular carcinoma. ( Principal Investigator(PI))
  22. 2008 - 2008, Sanofi-Aventis
    SAVE-ONCO: A multinational, randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous throboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy ( Consultant)

CONSULTANCY PROJECT


  • Msd Jcap Head & Neck Cancers Group Input Meeting, MSD, Professional Consultant (Ir., Ar., Sr., Ts., dsbnya)
    12 Nov 2022 - 12 Nov 2022 (International)
  • Jcap Upper Gi Cancer Regional Expert Input Forum, MERCK
    01 Dec 2020 - 01 Dec 2020 (International)
  • The 4th Expanded Asia Nsclc Virtual Advisory Board Meeting, Boehringer Ingelheim (Malaysia) Sdn Bhd
    01 Dec 2020 - 01 Dec 2020 (International)
  • Great Virtual Advisory Board Meeting On Early Stage Lung Cancer Management, AstraZeneca
    01 Dec 2020 - 01 Dec 2020 (International)
  • Regional Cancer Associated Vte Advisory Board, Pfizer (Malaysia) Sdn Bhd
    01 Nov 2020 - 01 Nov 2020 (International)
  • Ahli Jawatankuasa Penilaian Permohonan Program Phd 2020 - Mourad Seghir, University Malaya Medical Centre
    01 Nov 2020 - 01 Nov 2020 (National)
  • Msd Head and Neck Cancer Virtual Expert Input Forum, Merck Sharp & Dohme (Malaysia) Sdn Bhd
    01 Nov 2020 - 01 Nov 2020 (National)
  • Pencalonan Bagi Jawatankuasa Kecil Pendidikan Perubatan (Jkpp) dan Jawatankuasa Kecil Penilaian Kepakaran Perubatan (Jkkpkp) Majlis Perubatan Malaysia., Majlis Perubatan Malaysia
    01 Dec 2018 - 01 Dec 2019 (National)
  • Persatuan Guolin Qigong Malaysia-Medical Advisor, Persatuan GuoLin QiGong Malaysia
    01 Dec 2017 - 01 Dec 2019 (National)
  • Msd Advisory Services, MSD
    01 Nov 2017 - 01 Nov 2019 (International)
  • Penilaian Candidature Defence Untuk Calon Phd:Nor Aziyan Yahyah, Universiti Malaya
    01 Jan 2019 - 01 Jan 2019 (National)
  • Clinical Research Attachment-Chew Wei Zhuen, Univeriti Malaya
    01 Jan 2019 - 01 Jan 2019 (National)
  • Master of Clinical Oncology Final Examination Session 2018/2019, April 2019, Universiti Malaya
    01 Jan 2019 - 01 Jan 2019 (National)
  • Pelantikan Panel Seminar "Candidature Defence" Calon Ijazah Doktor Falsafah-Zulaikha Jamalludin (Mha140010), Universiti Malaya
    01 Jan 2019 - 01 Jan 2019 (National)
  • Pelantikan Panel Seminar "Proposal Defence" Calon Ijazah Doktor Falsafah-Hoang Anh Tung (Mva190018), Universiti Malaya
    01 Jan 2019 - 01 Jan 2019 (National)
  • Master of Clinical Oncology Part 2 Examination Session 2018/2019, April 2019, Universiti Malaya
    01 Jan 2019 - 01 Jan 2019 (National)
  • Master of Clinical Oncology Part 1 Examination Session 2018/2019, April 2019, Universiti Malaya
    01 Jan 2019 - 01 Jan 2019 (National)
  • My-Compassion (Malaysian Collaborative Meeting On Pain Specialists to Improve Oncology Management) Advisory Board as a Speaker and Panelist., MIMS MEDICA SDN BHD
    01 Dec 2018 - 01 Dec 2018 (National)
  • My-Compassion (Malaysian Collaborative Meeting On Pain Specialists to Improve Oncology Management) Advisory Board Meeting, MIMS
    01 Dec 2018 - 01 Dec 2018 (National)
  • Soft Tissue Sarcoma Advisory Board Meeting, Eli Lily
    01 Dec 2018 - 01 Dec 2018 (International)
  • Stage III Advisory Board Meeting, Asian Thoracic Oncology Research Group
    01 Dec 2018 - 01 Dec 2018 (International)
  • Mims Oncology Honorary Editorial Advisory Board, MIMS
    01 Dec 2018 - 01 Dec 2018 (National)
  • Peperiksaan Profesional Sarjana Muda Perubatan dan Sarjana Muda Pembedahan (MBBS) Peringkat 2, Sesi 2017/2018: Pelantikan "Pemeriksa Semasa" Kertas Osce, University Malaya
    01 Dec 2018 - 01 Dec 2018 (National)
  • Construing The Role of Adipokines and Their Mechanism in Renal Cell Carcinoma (Rcc) Resistance to Targeted Therapies, Fundamental Research Grant Scheme (FRGS)
    01 Jul 2018 - 01 Jul 2018 (National)
  • Ulasan Pakar Ke Atas Produk Yang Sedang Dinilai Untuk Pendaftar Oleh Pihak Berkuasa Kawalan Dadah (Pbkd), Pihak Berkuasa Kawalan Dadah (PBKD), Kementarian Kesihatan Malaysia
    01 Jul 2018 - 01 Jul 2018 (National)
  • Position Paper On Cardio-Oncology in Malaysia,  National Heart Association of Malaysia
    01 Dec 2017 - 01 Dec 2017 (National)
  • Breakthrough Cancer Pain Advisory Board Meeting, MIMS
    01 Nov 2017 - 01 Nov 2017 (National)
  • Em Asia Regional Breast Cancer Advisory Board Meeting, Pfizer (Malaysia) Sdn Bhd
    01 Nov 2017 - 01 Nov 2017 (International)
  • Drug Access Advisory Board, Pfizer and MIMS
    01 Nov 2017 - 01 Nov 2017 (National)
  • Ahli Panel Temuduga Bagi Calon Program Ijazah Sarjana Onkologi Klinikal, Sesi 2017/2018, University Malaya Medical Centre
    01 Mar 2017 - 01 Mar 2017 (National)
  • Afatinib Council of Experts Meeting, Boehringer Ingelheim
    01 Nov 2016 - 01 Nov 2016 (International)
  • Breast Cancer Advisory Board, Pfizer
    01 Nov 2016 - 01 Nov 2016 (International)
  • Avastin in Metastatic Colorectal Cancer (McRc) Advisory Board Meeting 2016, Roche Malaysia
    01 Nov 2016 - 01 Nov 2016 (National)
  • Roche Oncology Scientific Meeting (Rosm), Roche
    01 Oct 2016 - 01 Oct 2016 (International)
  • Radiotherapy and Oncology Department Plan for Health Metropolis Project, Universiti Malaya Health Metropolis
    01 Aug 2010 - 01 Aug 2016 (National)
  • Yayasan Sinchew Medical Advisory Board, Yayasan Sinchew
    01 Mar 2015 (National)
  • Nsclc Apsa Advisory Board, Novartis
    01 Dec 2015 - 01 Dec 2015 (International)
  • Mini Nsclc Adboard/ Nsclc Expert Summit, Boehringer Ingelheim
    01 Dec 2015 - 01 Dec 2015 (International)
  • Brcam Diagnostic Advisory Board, Astra Zeneca
    01 Dec 2015 - 01 Dec 2015 (National)
  • Mesyuarat Pembentukan Clinical Practice Guidelines (Cpg) Management of Cervical Cancer (Second Edition)-Bersama Review Committee Bil 02/2015, Kementarian Kesihatan Malaysia
    01 Sep 2014 - 01 Sep 2015 (National)
  • Asia Pcific Melanoma Expert Input Forum, MSD
    01 Feb 2015 - 01 Feb 2015 (International)
  • South East Asia & South Korea Second Line Nscls Advisory Board Meeting, Boehringer Ingelheim
    01 Nov 2014 - 01 Nov 2014 (International)
  • My-Sg Regrorafenib Advisory Board, Roche
    01 Nov 2014 - 01 Nov 2014 (International)
  • Advcanced Breast Cancer Advisory Board, Novartis
    01 Nov 2014 - 01 Nov 2014 (National)
  • 1st Asia Area Lung Cancer Advisory Board Meeting, Astra Zeneca
    01 Oct 2014 - 01 Oct 2014 (International)
  • Malaysia Afatinib Advisory Board, Boehringer Ingelheim
    01 Oct 2014 - 01 Oct 2014 (International)
  • 1.Overview of The New Acs Global Health Priorities;2.Successes in Cancer Control in Malaysia;3.What Are The Gaps in Cancer Prevention and Control., American Cancer Society
    01 Dec 2013 - 01 Dec 2013 (International)
  • Pertuzumab Advisory Board, Roche
    01 Jul 2013 - 01 Jul 2013 (National)
  • Global Stivarga Education Curriculum Review Meeting, Global Education Steering Committee and the Bayer Stivarga team
    01 Jun 2013 - 01 Jun 2013 (International)
  • 'Gamma Knife Radiosurgery for Recurrent Intracranial Olfactory Neuroblastoma (Esthesioneuroblastoma): a Case Report',Eduard B Dinca, Matthias Wr Radatz, Jeremy R Rowe and Andras a Kemeny,Journal of Medical Case Reports., The Journal of Medical Case Reports Editorial Team
    01 Jul 2012 - 01 Jul 2012 (International)
  • Establishment of Heavy Ion Particle Centre Health Metropolis, Toshiba Transmission & Distribution System Asia
    01 Jul 2012 - 01 Jul 2012 (International)
  • Asia-Pacific Conference On Management of Colorectal Cancer - a Round-Table Consensus, Merck Serono
    01 May 2012 - 01 May 2012 (National)
  • Review a Manuscript for World Journal of Surgical Oncology, The World Journal of Surgical Oncology Editorial Team
    01 Jul 2010 - 01 Jul 2010 (International)
  • 1. to Summarize The Efficacy and Safety Data for Lapatinib in Patients With Hormone Receptor (Hr) Sensitive Erbb2+ Metastatic Breast Cancer (Mbc). 2. to Review The Prevalence and Current Treatment Strategies for Hr+ Erbb2+ Mbc. 3. to Discuss The Optimization of Anti Erbb2 Treatment With Lapatinib in Hr+ Erbb2+ Mbc., GSK
    01 Jan 2010 - 01 Jan 2010 (National)
  • 1. Discuss Current Issues in Management of Renal Cell Carcinoma; 2. Identify Management and Educational Needs; 3. Establish Role of Mtor Inhibitors., Norvatis Oncology
    01 Jun 2009 - 01 Jun 2009 (National)

PAPER PRESENTED


INVITED SEMINAR
  1. ESMO ASIA 2017 Congress, ESMO ASIA 2017 Congress, ESMO ASIA 2017 Congress (International) (17 Nov 2017 - 19 Nov 2017)
  2. ESMO 2016 Congress, ESMO 2016 Congress, EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (International) (07 Oct 2016 - 11 Oct 2016)
  3. All About you have to know about Gynecologic Cancer, Seminar of Cancer Truth 4.0, Eu Yan Sang (National) (28 Aug 2016 - 31 Aug 2016)
  4. 3rd Asia-Pacific Gastroenterology Cancer Summit 2016, 3rd Asia-Pacific Gastroenterology Cancer Summit 2016, Singapore Society of Oncology (International) (29 Apr 2016 - 01 May 2016)
  5. OBSERVATIONAL PROSPECTIVE STUDY IN MANAGEMENT OF 1ST LINE KRAS WILDTYPE MCRC WITH ERBITUX (CETUXIMAB) - OPTIM1SE-INVESTIGATOR S MEETING, OBSERVATIONAL PROSPECTIVE STUDY IN MANAGEMENT OF 1ST LINE KRAS WILDTYPE MCRC WITH ERBITUX (CETUXIMAB) - OPTIM1SE-INVESTIGATOR S MEETING (International) (17 May 2014 - 17 May 2014)
  6. Cancer Control Leadership Forum, Cancer Control Leadership Forum, Kuala Lumpur (National) (31 Mar 2014 - 02 Apr 2014)
  7. Oncology Clinic (Practical Session), Capecitabine Perceptorship Program, Oncology Unit Unversity Malaya Medical Centre & Roche (International) (11 Mar 2014 - 15 Mar 2014)
INVITED SPEAKER
  1. Immunotherapy in Localised CRC: Are We There Yet?, 34th Annual Scientific Congress of Malaysian Oncological Society, Malaysian Oncological Society (National) (06 Oct 2023 - 08 Oct 2023)
  2. Excelling Clinical Trials in Oncology, UMMC RESEARCH CARNIVAL 2023, Universiti Malaya Medical Centre (National) (12 Sep 2023 - 12 Sep 2023)
  3. Rare Mutation Targeted Agents, Masterclass in systemic cancer therapy (MSCT) 2023, Department of Clinical Oncology, Universiti Malaya (National) (16 Jul 2023 - 16 Jul 2023)
  4. Deep dive into targeted therapies in EGFRm+ NSCLC mutations, Lung Cancer CME, Boehringer Ingelheim (Malaysia) Sdn. Bhd. (International) (20 May 2023 - 20 May 2023)
  5. Fire-Side Chat: Hot Topics in HR+/HER2-aBC, IGNITE Breast Cancer Symposium, Pfizer (National) (06 May 2023 - 06 May 2023)
  6. Oncology Clinical Trials at UMMC: Updated on GI Malignancies, Live Webinar Series: BREAKFAST@UMHEALTH, Universiti Malaya (University) (22 Mar 2023 - 22 Mar 2023)
  7. Malaysian Patients Access to Ground-breaking Cancer Therapies Through Clinical Trials in the Last Decade: Can we do more? A Perspective from UMMC, CRM TRIAL CONNECT 2022, Clinical Research Malaysia (National) (14 Oct 2022 - 14 Oct 2022)
  8. Molecular Tumor Board- Adjuvant and neoadjuvant treatment options in resectable and borderline resectable pancreatic cancer, Treatment approaches in locally advanced unresectable pancreatic cancer, management of metastatic cancer, 8th Asia-Pacific Gastroenterology Cancer Summit 2021, Index Conferences & Exhibitions Org. Est.  (International) (14 Aug 2021 - 15 Aug 2021)
  9. Panelist and Practical Case Discussion, Changing the Trajectory of MBC-A New Treatment Option, ZL Therapeutics  (National) (07 Aug 2021 - 07 Aug 2021)
  10. Ask the Experts: COVID-19 Vaccination in Cancer, UMMC-TAC Forum, University Malaya Medical Centre and Together Against Cancer (National) (21 Feb 2021 - 21 Feb 2021)
  11. Updates on non-surgical management of pancreatic cancers, 1st MyHPB Virtual Conference 2020 (MyHPB 2020), Malaysia Society of Hepato-Pancreato-Biliary Surgeon (MyHPBS) (National) (05 Dec 2020 - 05 Dec 2020)
  12. Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counselling during online testing for breast and ovarian cancer genetic risk., Best of ASCO-ASCO 20 Virtual in Malaysia, ASCO (National) (05 Dec 2020 - 06 Dec 2020)
  13. Real world experience with dacomitinib, PROMISE-Pfizer Oncology Meeting Integrating Scientific Evidences into Clinical Practice-Lung Cancer Track, Pfizer Malaysia (National) (31 Oct 2020 - 31 Oct 2020)
  14. Other rarer mutations/targets and intervention , Masterclass in Systemic Cancer Therapy-Understanding the science behind therapy., Malaysian Oncological Society, University of Malaya  (National) (11 Sep 2020 - 12 Sep 2020)
  15. Department of Clinical Oncology-Clinical Research Updates, Bridging Translational Cancer Research Forum , University of Malaya Cancer Research Institute (UMCRi) (National) (03 Mar 2020 - 03 Mar 2020)
  16. Immunotherapy for Solid Cancers: An Update, 1st Malaysian Association for Cancer Research (MACR) Scientific Conference 2019, Malaysian Association for Cancer Research and Masha University (National) (03 Dec 2019 - 04 Dec 2019)
  17. Immunotherapy for Solida Cancers: An Update , 1st Malaysian Association for Cancer Research (MACR) Scientific Conference, Malaysian Association for Cancer Research, MAHSA University (National) (03 Dec 2019 - 04 Dec 2019)
  18. CDK4/6i in Breast Cancer: What's New and What's Left to Learn, 31st ASCOMOS 2019, Malaysian Oncological Society (National) (01 Nov 2019 - 03 Nov 2019)
  19. Tissue Agnostic Therapy in Colorectal Cancer (CRC), 31st MOS Annual Scientific Congress 2019, Malaysian Oncological Society (National) (01 Nov 2019 - 03 Nov 2019)
  20. Evolution In Management Of Advanced HCC: The Power Of Combined Therapy, 6TH Asia Pacific Congress of International Oncology (APCIO) 2019 , Malaysian Society of Interventional Radiology (MYSIR) (International) (04 Oct 2019 - 04 Oct 2019)
  21. Locally Advanced Stage 3 NSCLC: Non-Surgical Option?, MTS Lung Cancer Pre-Congress Workshop, The Malaysian Thoracic Society (National) (18 Jul 2019 - 18 Jul 2019)
  22. Precision Radiotherapy in the 21st Century, Academy for Silent Mentor (AFSM) Tripartite Conference 2018, Academy for Silent Mentor (AFSM) and Asian Society of Cryosurgery (ASC) (International) (14 Dec 2018 - 15 Dec 2018)
  23. Treatment Option for Special Patient Population with EGFR M+ *Brain Metastasis *Uncommon Mutation., Sequencing in EGFR-mutated NSCLC: Does Order Matter? , Boehringer Ingelheim (Malaysia) Sdn Bhd (National) (08 Dec 2018 - 08 Dec 2018)
  24. Updates on Immunotherapy for Lung Cancers, International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM 18) Cancer Care, Malaysian Association for Cancer Research (International) (04 Dec 2018 - 05 Dec 2018)
  25. Translational Medicine for Ovary Cancer, International Conference on Obstetrics, Gynaecology and Pediatrics, International Conference on Obstetrics, Gynaecology and Pediatrics (National) (26 Nov 2018 - 28 Nov 2018)
  26. Modern Management of Breast Cancer, Excellence in Breast Cancer Therapy and Support Conference, Pink Ribbon Wellness (L) Foundation (National) (10 Aug 2018 - 12 Aug 2018)
  27. Thoracic Oncology (chemotherapy, radiation), Kuala Lumpur Cardiothoracic Review Course 2018, Malaysian Association for Thoracic & Cardiovascular Surgery & National Heart Institute (International) (07 Aug 2018 - 08 Aug 2018)
  28. Benefit of Extended Hormonal Therapy, 3rd Annual South East Asia Breast Cancer Symposium, SEABCS 2018 (International) (03 Aug 2018 - 05 Aug 2018)
  29. Case Presentation MBC & Discussion (Televoting), ASEAN Breast & GI Cancer Scientific Exchange Meeting , Eli Lily (International) (04 May 2018 - 04 May 2018)
  30. Oncology Panel Presentation, Oncological Management, Systemic Theraphy, MMI ONCOLOGY COLLOQUIUM 2018, MMI Oncology Colloquium (University) (03 Feb 2018 - 04 Feb 2018)
  31. Multi-Disciplinary Approach Symposium, Oncological Management-Systemic Theraphy, MMI Oncology Colloquium 2018, MMI Oncology Colloquium (University) (03 Feb 2018 - 04 Feb 2018)
  32. STRATEGIES FOR PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED MULTIPLE PRIOR THERAPIES. , 2nd International Clinical Oncology Congress , Iranian Society Of Clinical Oncology (International) (13 Dec 2017 - 15 Dec 2017)
  33. Genomic Landscape of CRC: A Therapeutic Roadmap, Annual Scientific Conference of the Malaysian Oncological Society 2017 , Malaysian Oncological Society  (International) (08 Dec 2017 - 10 Dec 2017)
  34. Cancer and You, 19th World of Chinese Book Fair , 19th World of Chinese Book Fair  (National) (24 Nov 2017 - 03 Dec 2017)
  35. Precision Medicine for Colorectal Cancer Liver Metastases - What's the status?, 11th National Conference for Clinical Research 2017, CREST EVENDZ SDN BHD (International) (27 Sep 2017 - 29 Sep 2017)
  36. Case Sharing, Merck Oncology Summit 2017, Merck Sdn Bhd (International) (26 Aug 2017 - 27 Aug 2017)
  37. Case sharing 1&2, GC symposium-Uncover the Unmet Needs in Treatment of Gastric Cancer, Eli Lily (National) (20 Aug 2017 - 20 Aug 2017)
  38. Evolution in Treatment of Lung Carcinoma, 3rd Johor Oncology Meeting 2017-Cancer is a Word Not a Sentence, 3rd Johor Oncology Meeting 2017 (International) (05 Aug 2017 - 05 Aug 2017)
  39. Current Update in the Breast Cancer Management, Breast Cancer Survivor s Workshop, Pink Ribbon Wellness (L) Foundation.  (National) (14 May 2017 - 14 May 2017)
  40. Understanding Your Chemo and Hormone Therapies Panel Discussion, Breast Cancer Survivor s Workshop, Pink Ribbon Wellness (L) Foundation.  (National) (14 May 2017 - 14 May 2017)
  41. Upper GI a cancer case presentation and Panel, 4th Asia-Pacific Gastroenterology Cancer Summit 2017, Asia-Pacific Gastroenterology Cancer (International) (29 Apr 2017 - 30 Apr 2017)
  42. Update in systemic therapy for colorectal liver metastases., COLOPROCTOLOGY 2017, Malaysian Society of Colorectal Surgeons. (International) (09 Mar 2017 - 12 Mar 2017)
  43. Immuno-Oncology, Masterclass in Systematic Cancer Therapy, Malaysian Oncological Society , University Malaya Medical Centre (National) (04 Mar 2017 - 05 Mar 2017)
  44. Case-presentation (fulvestrant monotherapy in management of ER+ ABC), National Oncology Summit 2017-Reaching New Heights in Ovarian, Lung and Breast Cancer Care (Conference), AstraZeneca (International) (25 Feb 2017 - 26 Feb 2017)
  45. Case study on fulvestrant monotherapy in the management of ER+ advanced breast cancer., National Oncology Summit 2017, Malaysian Oncology Society and AstraZeneca (International) (25 Feb 2017 - 26 Feb 2017)
  46. Adjuvant aspirin for colorectal cancer? A cross-Asia collaborative effort., EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ASIA 2016., EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (International) (17 Dec 2016 - 17 Dec 2016)
  47. Nasopharyngeal carcinoma (NPC) T Cell treatment, Annual Scientific Conference of the Malaysian Oncological Society 2016, Malaysian Oncological Society (International) (13 Oct 2016 - 16 Oct 2016)
  48. Personalised therapy in NSCLC-ALK, ROS1 positive, Advanced Lung Cancer Academia, Boehringer Ingelheim (Malaysia) Sdn Bhd (International) (03 Sep 2016 - 03 Sep 2016)
  49. Staging for Cancers, Pre-Congress Workshop-Annual Scientific Congress College of Surgeons Malaysia 2016 Masterclass in Breast & Colorectal Cancer Surgery for Community Surgeons and Practitioners, College of Surgeons Malaysia (National) (11 May 2016 - 11 May 2016)
  50. Chemoradiation in Colorectal Cancer, Pre-Congress Workshop-Annual Scientific Congress College of Surgeons Malaysia 2016 Masterclass in Breast & Colorectal Cancer Surgery for Community Surgeons and Practitioners, College of Surgeons Malaysia (National) (11 May 2016 - 11 May 2016)
  51. The medical information which patient should know. , Cancer Truth Seminar 3.0 , Eu Yan Sang (National) (15 Nov 2015 - 15 Nov 2015)
  52. How to minimize recurrent, 2nd UMMC Breast Cancer Public Forum- Living Well with Breast Cancer (National) (25 Oct 2015)
  53. Breast Cancer-Update on HER2 +VE , Malaysia Oncological Society (MOS) Annual Scientific Meeting 2015 "Evolving Trends in Oncology - From Molecules to Man." , Malaysia Oncological Society (MOS)  (International) (17 Oct 2015 - 17 Oct 2015)
  54. The medical information which patient should know. , Cancer Truth Seminar 3.0, Eu Yan Sang (National) (22 Aug 2015 - 22 Aug 2015)
  55. The medical information which patient should know. , Cancer Truth Seminar 3.0, Eu Yan Sang (National) (21 Aug 2015 - 21 Aug 2015)
  56. Case Presentation & Discussion 1, Personalized Therapy for mCRC patients (National) (08 Aug 2015)
  57. Personalised Breast Cancer Treatment, 13th Asia Breast Diseases Association Teaching Course (01 Aug 2015 - 01 Aug 2015)
  58. Personalized Breast Cancer Treatment, 13th Asian Breast Diseases Association (ABDA) Teaching Course (International) (01 Aug 2015)
  59. Introduction & Welcoming Speech, Stereotactic Radiosurgery/Radiotherapy for Cranial Lesions Workshop (University) (11 May 2015 - 11 May 2015)
  60. Targeted therapy in NSCLS-The Asian Experience, Respiratory Forum, boehringer-ingelheim (International) (26 Apr 2015 - 26 Apr 2015)
  61. Nindetanib-Clinical Updates in NSCLC, Respiratory Forum, boehringer-ingelheim (International) (26 Apr 2015 - 26 Apr 2015)
  62. Yttrium- 90 Radioembolization: Safe and Effective Treatment? (With Biologics, Anti -VEGF, EGFR/K-Ras and RAF Mutants), National Radioembolisation Symposium 2015 , Institut Kanser Negara  (National) (25 Mar 2015)
  63. Primary and secondary Liver cancer treatment TACE/SIRT/BCLC/Sorafanib-Oncologist Perspective , National Radioembolisation Symposium 2015, Institut Kanser Negara (National) (23 Mar 2015)
  64. Tamoxifen- New Updates, Life Beyond Breast Cancer-Teaching Symposium for Survivors, Pink Ribbon Wellness (L) Foundation  (National) (20 Mar 2015 - 20 Mar 2015)
  65. "What is the standard of care of Adjuvant Radiotherapy : Hypofractionated or Evolving New Radiotherapy Techniques", Highlights of ESMO 2014 Congress-South East Asia Summit- "Precision Medicine in Cancer Care"  (International) (24 Jan 2015)
  66. A challenging case in Lung Cancer - East Meets West - "The Young Patient with NSCLC : The treatment paradigms we face in our clinic today , Highlights of ESMO 2014 Congress-South East Asia Summit- "Precision Medicine in Cancer Care" (International) (23 Jan 2015 - 25 Jan 2015)
  67. Cancer and Health, 2 Days Body, Mind & Soul Health Workshop, Natural Green House (National) (13 Dec 2014 - 14 Dec 2014)
  68. About cancer, About cancer, Natural Green House (13 Dec 2014)
  69. How to help cancer patients?, National seminar, Persatuan GuoLin QiGong Malaysia (National) (22 Nov 2014 - 22 Nov 2014)
  70. Debate: HIPEC is a MUST for CRC Peritoneal Carcinomatosis , 2nd Asia Pacific Gastroenterology Cancer Summit 2014 (APGCS) (International) (15 Nov 2014 - 16 Nov 2014)
  71. Radiotherapy, 1st UMMC Breast Cancer Public Forum  (National) (18 Oct 2014)
  72. The overview on symptoms in cancer and side effects on cancer treatment, Kursus Clinical Dietetic Updated (CDU) in Nutrition Management of Cancer 2014 (National) (08 Oct 2014 - 09 Oct 2014)
  73. Introduction of cancer and latest progress in cancer treatment, Fact of Cancer 2.0, Eu Yan Sang (National) (10 Aug 2014 - 10 Aug 2014)
  74. Introduction of cancer and latest progress in cancer treatment, Fact of Cancer 2.0, Eu Yan Sang (National) (03 Aug 2014 - 03 Aug 2014)
  75. Doctors vs. patients., BookFest @ Malaysia 2014, POPULAR (International) (29 Jul 2014 - 29 Jul 2014)
  76. THE CHALLENGE AND ALTERNATIVES OF MEDICAL TREATMENT FOR BREAST CANCER IN ASIA, 11TH INTERNATIONAL CONFERENCE OF ASIA CLINICAL ONCOLOGY SOCIETY IN CONJUNCTION WITH 19TH TAIWAN JOINT CANCER CONFERENCE , The Chinese Oncology Society, Taiwan ROC  (International) (02 May 2014 - 04 May 2014)
  77. update on PNET/ Germ cell tumors, MOSART workshop (National) (26 Apr 2014)
  78. Primary and Secondary Liver Cancer Treatment: TACE/SIRT/BCLC/Sorafanib - Oncologist Perspective, National Radioembolisation/SIRT Symposium (IAEA MAL 6020) (23 Mar 2014 - 25 Mar 2014)
  79. Debate: First Line Metastatic Treatment of Pancreatic Cancer: What is the Best Regimen?--The Case of FOLFIRINOX, Asia-Pacific Gastroenterology Cancer Summit 2013, APGCS 2013 (International) (06 Dec 2013 - 08 Dec 2013)
  80. Breast Cancer Tumour Board: To Predict or Not, Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (30 Nov 2013)
  81. Prevention and Recurrent Risk Management of Cancer, Prevention and Recurrent Risk Management of Cancer, Pay Fong Alumni and International Rehabilitation of Cancer Association (IRCA),Malaysia.  (National) (23 Nov 2013)
  82. Breast Cancer Services Performance in Malaysia., Singapore-Malaysia Breast Cancer Working Group (SMBCWG):Reseach Meet 2013, CRC, UMCRI, Academic of Medicine of Malaysia. (International) (28 Oct 2013 - 29 Oct 2013)
  83. Know Cancer to Keep it At Bay!, Pink October:Breast Cancer Awareness Month, Jing Si Book & Cafe (National) (26 Oct 2013)
  84. How do Cancer Patient handle their Life?, Persatuan GuoLin QiGong Malaysia 20th Year Anniversary Activity , Sin Chew Daily and Persatuan GuoLin QiGong Malaysia (National) (19 Oct 2013)
  85. Patient Access to Colorectal Cancer Treatment, Advocacy strategies in the fight against colorectal cancer and access to treatment, Colorectal Cancer Patient Support Group(CORUM)  (International) (17 Aug 2013)
  86. Cancer: An Introduction, The Fact of Cancer , Eu Yan Seng (International) (14 Jul 2013)
  87. Cases Discussion, "Connectin g the Dots..." A MDT workshop on the management of colorectal cancer , Merck Serono (National) (29 Jun 2013)
  88. Cancer vs. Vegetarian, Tzu Chi Health Talk, Tzu Chi Foundation (National) (15 Jun 2013)
  89. Getting to know Cancer and don't afraid it!, Sinchew Daily Talk , Sinchew Daily  (National) (08 Jun 2013 - 08 Jun 2013)
  90. Understanding cancer and cancer treatment, Palliative care, pain management, understanding cancer and treatment in western medicine and chinese medicine perspective, spiritual spport & communication skills Course, Tzu Chi TIMA core group (06 Apr 2013 - 06 Apr 2013)
  91. Life Beyond Breast Cancer, Breast Cancer Support Symposium (18 Oct 2012 - 20 Oct 2012)
  92. European Society of Medical Oncology (ESMO) Colorectal Cancer Study Day, European Society of Medical Oncology (ESMO) Colorectal Cancer Study Day (13 Oct 2012)
  93. Cancer and you, Tzu Chi Health Talk, Tzu Chi Foundation (15 Sep 2012)
  94. 6D Ovarian Cancer Adjuvant Chemotherapy , Malaysian Oncological Society Annual Conference (ASCOMOS), Malaysian Oncological Society (MOS) (06 Sep 2012 - 09 Sep 2012)
  95. HER2-positive metastatic breast cancer: the role of targeted therapy beyond trastuzumab., MOS-GSK Collaborative Symposium on Metastatic Breast Cancer , MOS-GSK (National) (23 Jun 2012)
  96. General knowledge of CA, Tzu Chi Medical Talk, Tzu Chi Foundation (National) (23 Jun 2012)
  97. Barriers To Clinical Trials In Asia, 6th General Assembly of the Asia Pacific Organization for Cancer Prevention (26 Apr 2012 - 29 Apr 2012)
  98. Kian Kok Middle School Cancer Awareness Evening, Kian Kok Middle School Cancer Awareness Evening (14 Apr 2012)
  99. Pazopanib- a case study, Optimizing treatment in mRCC (International) (14 Apr 2012)
  100. General knowledge of CA, Tzu Chi Foundation talk, Tzu Chi Foundation  (National) (01 Apr 2012)
  101. Locally Advanced Prostate Cancer, The 2nd Art of Uro-Oncology Prostate Cancer Meeting, Sanofi Oncology (International) (18 Feb 2012 - 19 Feb 2012)
  102. Sarawak Cancer Society Lung Cancer Study Day(Public), Sarawak Cancer Society Lung Cancer Study Day (National) (19 Nov 2011)
  103. Sarawak Cancer Society Lung Cancer Study Day, Sarawak Cancer Society Lung Cancer Study Day(Club)  (National) (19 Nov 2011)
  104. Tzu Chi Foundation Health Talk Event, Tzu Chi Foundation Health Talk Event (19 Nov 2011)
  105. Adjuvant therapy in pancreatic cancer - are we making an impact?, 21st Asia Pacific Cancer Conference 2011 (International) (10 Nov 2011)
  106. New Angles, New Facets, New Perspectives, Highlights from the The Art of Oncology Breast Cancer Meeting 2011, UBM Medica Malaysia (International) (12 Aug 2011 - 12 Aug 2011)
  107. Review the latest updates in breast cancer management, with plenary lectures and patientcase discussion., Art of Oncology Breast Cancer Conference:Asia-pacific oncology conference (23 Jul 2011 - 24 Jul 2011)
  108. Practice Advances in Chemotherapy, The Art of Oncology Breast Cancer Meeting New Angles, New Facets, New Perspectives (11 Jun 2011 - 12 Jun 2011)
  109. International Metastatic bone disease symposium, International Metastatic bone disease symposium (21 May 2011)
  110. General knowledge of CA, Tzu Chi Foundation Health Talk Event (24 Apr 2011)
  111. Herceptin Targeted therapy for HER 2+ve Breast Cancer, ADVANCES IN ONCOLOGY THERAPEUTICS, Myanmar Oncology Society (28 Nov 2010)
  112. Then role of MTOR inhibitors in managing metastatics renal cell carcinoma., Novartis Oncology Free Standing Symposium & RCC Advisory Board Meeting (13 Nov 2010 - 14 Nov 2010)
  113. Optimizing treatment of HER2 Breast Cancer + Case presentation , Roche Asia-Pacific Oncology Conference, Bali on GI Cancers. (29 Oct 2010)
  114. Co-Chairperson for Research Paper Presentation Session, ASCOMOS 2010, ASCOMOS 2010, Annual Scientific Congress of Malaysian Oncological Society  (International) (02 Oct 2010)
  115. Pharmacy Study Day, Pharmacy Study Day (02 Oct 2010)
  116. Advances in Ovarian Cancer Chemothera py, MOS Annual Scientific Meeting Gyneacological Malignancy (02 Oct 2010)
  117. General knowledge of CA, Health talk in Tzu Chi, Tzu Chi Kelana Jaya office (National) (18 Sep 2010)
  118. Second Line Treatment of Advanced Renal cell Carcinoma, Malaysian-Oncology Society and MOS Renal Study Day (17 Jul 2010 - 18 Jul 2010)
  119. Medical Management in Inoperable Hepatocellular Carcinoma, Malaysian-Egyptian Oncology Society Meeting Hepatocellular Carcinoma, ASCO-MOS (01 May 2010)
  120. General knowledge of CA, Tzu Chi Health Talk, Tzu Chi USJ (National) (19 Mar 2010)
  121. ASIAN BREAST DISEASES ASSOCIATIO N 7TH TEACHING COURSE , Asian Breast Disease Association (ABDA) meeting , ASIAN BREAST DISEASES ASSOCIATIO N (01 Nov 2009 - 02 Jun 2013)
  122. radiotherapy for lung cancer, Lung Cancer symposium (12 Sep 2009)
  123. organ preservation treatment for larynx cancer, ENT society / MOS H&N cancer study (05 Sep 2009)
  124. Sanofi Aventis / MOS BREAST / Head / neck study days, Sanofi Aventis / MOS BREAST / Head / neck study days (08 Aug 2009)
  125. East Coast Cancer Symposium, East Coast Cancer Symposium (11 Jul 2009)
  126. Management of nasopharynx cancer, International Medical Univercity Oncology module (13 Jun 2009)
  127. 4D Radiotherapy, UM CBIE radiology study day (06 Jun 2009)
  128. Prostate Cancer Chemotherapy, Malaysian Urology Society Annual Meeting On (17 Oct 2008)
  129. Asco Update On Head And Neck Cancer, Malaysian Oncology Society/Singapore Oncology Society/Indonesian Oncology Society Joint Conference (21 Jun 2008)
  130. Image Guided Radiotherapy, Continuing Biomedical Imaging Education (Cbie) (25 Apr 2008)
  131. Taxanes For Breast Cancer, First Ukm Breast Cancer Weekend Meeting (26 Jan 2008)
EVENT ORGANISER
  1. 2020 Tzu-Chi TIMA (Tzu Chi International Medical Association) Convention, 2020 Tzu-Chi TIMA (Tzu Chi International Medical Association) Convention, TIMA (Tzu Chi International Medical Association) and Taiwan Buddhist Tzu-Chi Foundation Malaysia (KL-Selangor)  (National) (01 Oct 2020 - 03 Oct 2020)
  2. Translating the Essentials of Tumor Immunology to Clinical Applications, Immuno Oncology: New In Cancer Treatment (ICONIC) Educational Program , AstraZeneca (University) (11 Mar 2018 - 11 Mar 2018)
  3. Championing Cancer Care in Malaysia, Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society, ASCOMOS 2013 (International) (29 Nov 2013 - 01 Dec 2013)
  4. Chairperson/How to optimize renal cell cancer treatment with pazopanib in Malaysia? Impact of efficacy and safety profile, physicians and patients preference,accessibility and future trial., GSK Malaysia Pazopanib Advisory Board (26 Jun 2010)
ORAL PRESENTER
  1. A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR), ESMO ASIA 2023, ESMO (International) (01 Dec 2023 - 03 Dec 2023)
  2. The Prevalence of PIK3CA Mutations in Malaysian Breast Cancer Patients, 33rd Annual Scientific Congress of Malaysian Oncological Society 2022, Malaysian Oncological Society (National) (04 Nov 2022 - 06 Nov 2022)
  3. IN-VIVO SKIN DOSE MEASUREMENT USING MOSKIN DETECTOR DURING BREAST RADIOTHERAPY , 13th Asia-Oceania Congress of Medical Physics (AOCMP) and 11th South-East Asian Congress of Medical Physics (SEACOMP). , Asia-Oceania Federation of Organizations for Medical Physics (AFOMP), the South-East Asian Federation of Organizations for Medical Physics (SEAFOMP) and the Society of Medical Physicists (Singapore),  (International) (12 Dec 2013 - 14 Dec 2013)
  4. What is the Role of Progesterone Receptor in Estrogen Receptor Positive Breast Cancer?, Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (30 Nov 2013)
POSTER PRESENTER
  1. Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation positive NSCLC: An interim analysis of the ARIA study, ESMO 2023, ESMO (International) (19 Oct 2023 - 24 Oct 2023)
  2. Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial., ESMO 2023, ESMO (International) (19 Oct 2023 - 24 Oct 2023)
  3. Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122., American Association for Cancer Research Annual Meeting 2023, American Association for Cancer Research (International) (14 Apr 2023 - 19 Apr 2023)
  4. Intracranial activity of dacomitinib in treatmnet naive advanced EGFR mutated non-small cell lung cancer (NSCLC)-prespecified subgroup analysis of the ATORG-003 trial, ESMO Asis 2022, European Society for Medical Oncology (International) (02 Dec 2022 - 04 Dec 2022)
  5. Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1, ESMO Asia Congress 2022, European Society for Medical Oncology (International) (02 Dec 2022 - 04 Dec 2022)
  6. Health-Related Quality of Life With Pembrolizumab Versus Chemotherapy in Platinum-Pretreated Recurrent or Metastatic Nasopharyngeal Cancer: Phase 3 KEYNOTE-122 Study, ESMO Immuno-Oncology Congress 2021, European Society for Medical Oncology (International) (08 Dec 2021 - 11 Dec 2021)
  7. Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study, ESMO Asia Virtual Congress 2020, ESMO (International) (20 Nov 2020 - 22 Nov 2020)
  8. A Single Institutional Audit Of Setup Errors for Three Dimensional Conformal Radiotherapy (3DCRT) Rectal Cancers , ESTRO meets Asia 2019 , European Society for Radiotherapy & Oncology (International) (06 Dec 2019 - 08 Dec 2019)
  9. A Single Institutional Audit Of Setup Errors for Three Dimensional Conformal Radiotherapy (3DCRT) Rectal Cancers, ESTRO meets Asia 2019 , European Society for Radiotherapy & Oncology (International) (06 Dec 2019 - 08 Dec 2019)
  10. Hyperprogression after Pembrolizumab in Recurrent Oropharyneal Cancer and the use of Nab-Paclitaxel as Salvage Treatment-A Case Report, ESMO Asia 2019 Congress, ESMO (International) (22 Nov 2019 - 24 Nov 2019)
  11. The Response to Anapastic Lymphoma Kinase (ALK) Inhibitor in Metastatic Anaplastic Thyroid Carcinoma (ATC) , ESMO Asia 2019 Congress, ESMO (International) (22 Nov 2019 - 24 Nov 2019)
  12. Comparison of Pattern of Disease Progression and Prevalence of Acquired T790M Mutation in Malaysia Patients with EGFR Mutant Lung Adenocarcinoma upon Failure of First-line Afatinib, Gefitinib and Erlotinib, ESMO Asia 2019 Congress, ESMO (International) (22 Nov 2019 - 24 Nov 2019)
  13. In vivo dosimetry using MOSkin detector during high-dose rate brachytherapy of skin cancer, 18th Asia-Oceania Congress of Medical Physics (AOCMP) in conjunction with the 16th South-East Asia Congress of Medical Physics (SEACOMP), Asia-Oceania Congress of Medical Physics (AOCMP) 2018 (International) (11 Nov 2018 - 14 Nov 2018)
  14. An Open-label, Randomized Phase III Trial of Gemcitabine and Carboplatin (GC) Followed by Epstein-Barr Visrus-specific Autologous Cytotoxic T Lymphocytes (EBV-CTLs) Versus GC Alone as First-Line Therapy for Patients with Advcanced Nasopharyngeal Carcinoma (NPC), ASCO Annual Meeting 2018, ASCO (International) (01 Jun 2018 - 05 Jun 2018)
  15. External Audotory Meatus Involvement in Nasopharyngel Carcinoma: Two Contrasting Outcomes., ESMO Asia 2017 Congress , ESMO Asia 2017 (International) (17 Nov 2017 - 19 Nov 2017)
  16. Clinicians' Views on Utility of Risk Preduction Models For Early Stage Breast Cancer in Asia Pacific. , The National Conference for Clinical Research 2017, CREST EVENDZ SDN BHD (International) (27 Sep 2017 - 29 Sep 2017)
  17. KEYNOTE-394: Randomized Phase 3 Study of Pembrolizumab Versus Placebo With Best Supportive Care in Asian Patients for Second-Line Treatment of Advanced Hepatocellular Carcinoma, 20th Annual Meeting of Chinese Society of Clinical Oncology , Chinese Society of Clinical Oncology  (International) (26 Sep 2017 - 30 Oct 2017)
  18. Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. , American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, American Society of Clinical Oncology (ASCO)  (International) (02 Jun 2017 - 06 Jun 2017)
  19. Prospective, non-randomised, open-label study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy. , 40th ESMO European Cancer Congress  (International) (25 Sep 2015 - 29 Sep 2015)
  20. Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country. , 40th ESMO European Cancer Congress  (International) (25 Sep 2015 - 29 Sep 2015)
  21. Budget Impact Analysis (BIA) to assess the affordability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treament for EGFR mutation positive (EGFR+) non-small cell lung cancers., 2014 IASLC ASia Pacific Lung Cancer Conference (APLCC) (International) (07 Nov 2014)
  22. Distress and psychiatric morbidity in cancer patients: Prevalence and association with mortality in a two-year longitudinal study., 2014 American Society of Clinical Oncology (ASCO) Annual Meeting (International) (30 May 2014 - 03 Jun 2014)
  23. Induction and concurrent chemoradiotherapy with cetuximab for patients with locally advanced nasopharyngeal carcinoma , 3rd NPC Research Day, Nasopharyngeal Carcinoma Society of Malaysia (National) (31 Mar 2014)
  24. Phase II Trial of Maintenance Metronomic Chemotheraphy in Patients with Hormone Resistant Metastatic Breast Cancer with Favourable responce to induction chemotheraphy. , Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (29 Nov 2013 - 01 Dec 2013)
  25. Regorafenib after Progression on Prior Standard Therapies for Metastatic Colorectal Cancer: A Case Series from a Single Cenre. , Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society. , ASCOMOS 2013 (International) (29 Nov 2013 - 01 Dec 2013)
  26. Alpha-1-Acid Glycoprotein, A Potential Predictive Biomaker of Docetaxel Adverse Effects in Malaysian Breast Cancer Patients. , Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (29 Nov 2013 - 01 Dec 2013)
  27. CT-Based 3D Treatment Planning of Co-60 HDR Intracavitary Brachytherapy:A Comparison between Volumetric and ICRU Point of Rectum and Bladder., Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (29 Nov 2013 - 01 Dec 2013)
  28. Afatinib in Heavily Pre-Treated Metastatic Adenocarcinoma Lung Patients at Disease Progression: 2 Case Reports. , Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (29 Nov 2013 - 01 Dec 2013)
  29. What is the Role of Progesterone Receptor in Estrogen Receptor Positive Breast Cancer? , Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (29 Nov 2013 - 01 Dec 2013)
  30. Everolimus in a Case of Metastatic Pancreatic Neuroendocrine Tumor, ASCOMOS 2012, Malaysian Oncological Society (MOS) (International) (07 Sep 2012 - 08 Sep 2012)
  31. Adjuvant Chemotherapy for Colorectal Cancers: Are We Making the Right Choice? , ASCOMOS 2012, Malaysian Oncological Society (MOS) (International) (07 Sep 2012 - 08 Sep 2012)
  32. The Effect Of CYP2D6 Genetic Polymorphisms On Survival In Malaysian Women With ER Positive Breast Cancer Treated With Tamoxifen., 6th General Assembly of the Asia Pacific Organization for Cancer Prevention , Asian Pacific Organization For Cancer Prevention (International) (26 Apr 2012 - 29 Apr 2012)
  33. 3 Poster for Malaysian Oncology Society annual conference , , Malaysian Oncology Society annual conference (07 Nov 2009)
  34. 2 posters for Asia-pacific Oncology Summit, 2 posters for Asia-pacific Oncology Summit (03 Oct 2009)
  35. Asian Oncology Summit meeting, Asian Oncology Summit meeting (07 Mar 2009)
  36. Craniospinal Radiotherapy Technique(First Runner-Up For Best Poster), Malaysian Oncology Society Meeting (23 Oct 2008)
  37. Reirradiation Of Neck Post -Chemoradiation, Malaysian Oncology Society Meeting (National) (23 Oct 2008)
  38. Conformal Radiotherapy To Large Breast Using Segmented Fields, Asia-Oceania Congress Of Medical Physics & South-East Asian Congress Of Medical Physics (18 Oct 2008)
  39. Induction and concurrent chemoradiation for lung cancer with cisplatin and vinorelbine, British Thoracic Oncology Group (BTOG) meeting (03 Jan 2008)
PRESENTER
  1. Live Case Demonstrations, Multidisciplinary Oncology Symposium Malaysia 2017 , Multidisciplinary Oncology Symposium Malaysia  (International) (11 May 2017 - 14 May 2017)
  2. TIMA (Tzu Chi International Medical Association) Conference 2017, TIMA (Tzu Chi International Medical Association) Conference 2017, TIMA (Tzu Chi International Medical Association) (International) (17 Mar 2017 - 19 Mar 2017)
  3. Performanc of Lung Cancer Care services in a middle income developing country Malaysia. , 2014 IASLC ASia Pacific Lung Cancer Conference (APLCC) (International) (06 Nov 2014)
  4. What if all cancer patients in Malaysia have access to the best available care: How many deaths are avoidable?, 6th Asian Oncology Summit and 10th Annual Conference of the Organisation for Oncology and Translational Research  (International) (11 Apr 2014 - 13 Apr 2014)
  5. Closing the Cancer Divide: Performance of Breast Cancer Care in the middle income country Malaysia., Asian Oncology Summit (International) (22 Mar 2013 - 24 Mar 2013)
  6. Extended-field irradiation (EFRT) and intra-cavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic lymph nodes, Asian Oncology Summit 2009 (01 Mar 2009)
  7. Lecture/Case Study presentation to XPERT (Xeloda) meeting in Penang, XPERT (Xeloda) meeting (30 Aug 2008)
  8. Cetuximab And Chemoradiation For Locally Advanced Nasopharyngeal Carcinoma, Designed And Initiated Clinical Research on Cetuximab And Chemoradiation For Locally Advanced Nasopharyngeal Carcinoma (09 Aug 2008)
  9. Computerized versus Conventional Planning for Craniospinal Irradiation of Medulloblastoma A Dosimetric Study, Runner-up for best poster in Malaysia Oncological Society Meeting (01 Mar 2008)
  10. Pitfalls in radiotherapy Reirradiation for head and neck cancers , Malaysia Oncological Society Meeting (01 Mar 2008)
  11. Induction and concurrent chemoradiotherapy for non-small cell lung cancer (NSCLC) using cisplatin and vinorelbine, British Thoracic Oncology Group Annual Conference (01 Mar 2008)
  12. Chemoradiotherapy for locally advanced head and neck cancer using weekly cisplatin, British Cancer Research Meeting (01 Mar 2005)
  13. Long term outcome of chemoradiation to bladder cancer using MOPq10 regime, National Cancer Research Institute meeting (01 Mar 2005)
OTHERS
  1. Evolving Treatment Paradigm in Ovarian Cancer, Women s Cancer Summit 2019: Redefining the Treatment Paradigm in Ovarian and Breast Cancer, AstraZeneca and Malaysian Oncological Society (National) (15 Jun 2019 - 15 Jun 2019)
  2. Current Challenges in Breast Cancer: Where are we now., Women s Cancer Summit 2019: Redefining the Treatment Paradigm in Ovarian and Breast Cancer, AstraZeneca and Malaysian Oncological Society (National) (15 Jun 2019 - 15 Jun 2019)
  3. Abstral A New Frontier in the Management of Breakthrough Cancer Pain, Lunch Symposium during the 52nd Malaysia-Singapore Academy of Medicine, A. Menarini Singapore Pte Ltd (International) (27 Jul 2018 - 27 Jul 2018)
  4. ACOS Conference, ACOS Conference, Asian Clinical Oncology Society (International) (23 Feb 2018 - 25 Feb 2018)
  5. War on Cancer: Malaysia, War on Cancer: Malaysia, The Economist (National) (22 Feb 2018 - 22 Feb 2018)
  6. Oncology Case Presentation, MMI ONCOLOGY COLLOQUIUM 2018, MMI ONCOLOGY  (University) (03 Feb 2018 - 04 Feb 2018)
  7. Role of Nanomedicine in aggressive Metastatic Pancreatic Cancer and Non-Small Cell Lung Cancer, Annual Scientific Conference of the Malaysian Oncological Society 2017, Malaysian Oncological Society (International) (10 Dec 2017 - 10 Dec 2017)
  8. Breast Cancer 2, Annual Scientific Conference of the Malaysian Oncological Society 2017 , Malaysian Oncological Society (International) (08 Dec 2017 - 10 Dec 2017)
  9. Upper GI Cancer, Annual Scientific Conference of the Malaysian Oncological Society 2017 , Malaysian Oncological Society (International) (08 Dec 2017 - 10 Dec 2017)
  10. Masterclass in cTACE & Multidisciplinary Oncology Symposium Malaysia 2017, Masterclass in cTACE & Multidisciplinary Oncology Symposium Malaysia 2017, Malaysian Society of Interventional Radiology (MySIR), Malaysian Medical Association (MMA) Selangor and Wilayah; and the Asia-Pacific Association of Image-Guided Therapy in Oncology (APAITO), Malaysian Oncological Society (MOS) and the Asia Pacific Society of Cardiovascular & Interventional Radiology (APSCVIR).T (International) (12 May 2017 - 14 May 2017)
  11. Ovarian Ca Dinner Symposium, National Oncology Summit 2017-Reaching New Heights in Ovarian, Lung and Breast Cancer Care, Malaysian Oncology Society and Astra Zeneca (International) (25 Feb 2017 - 26 Feb 2017)
  12. Optimising Treatment Strategies in the Management of Advanced Pancreatic Cancer, Breakfast Symposium at ASCOMOS 2016 (Annual Scientific Conference of the Malaysian Oncological Society), Celgene. (National) (13 Nov 2016 - 13 Nov 2016)
  13. 2016 the Japanese Society of Medical Oncology Anuual Meeting, 2016 the Japanese Society of Medical Oncology Anuual Meeting, Japanese Society of Medical Oncology (International) (28 Jul 2016 - 30 Jul 2016)
  14. BRCA Mutation Prevalence Study and Sentinel Workshop, BRCA Mutation Prevalence Study and Sentinel Workshop, Obstetrical and Gynaecological Society of Malaysia (OGSM), Cancer Research Malaysia  (National) (10 Jan 2016 - 10 Jan 2016)
  15. ESMO Asia Conference , ESMO Asia Conference  (International) (18 Dec 2015 - 21 Dec 2015)
  16. IMMUNOTHERAPY, Malaysia Oncological Society (MOS) Annual Scientific Meeting 2015 "Evolving Trends in Oncology - From Molecules to Man." (International) (18 Oct 2015)
  17. Achieve Individual Health and Community Wellbeing, 2015 Kolisko Conference Malaysia , The Medical Section of the School of Spiritual Science Gotheannum Dornach Switzerland Anthroposophy Healthy Community Malaysia (International) (28 May 2015 - 31 May 2015)
  18. Treatment Planning for Clinicians (Introduction to Radiosurgery), Treatment Planning for Clinicians (Introduction to Radiosurgery), Brainlab Academy (International) (08 Mar 2015 - 11 Mar 2015)
  19. IMRT Head and Neck Workshop, IMRT Head and Neck Workshop, Insitut Kanser Negara (National) (22 Dec 2014 - 24 Dec 2014)
  20. Concurrent Session 7C: Lung Cancer Research, 2014 IASLC Asia Pacific Lung Cancer Conference (APLCC) (International) (06 Nov 2014 - 08 Nov 2014)
  21. Asia Experience Exchange for Patient Organisations, Asia Experience Exchange for Patient Organisations, Roche (International) (29 Oct 2014 - 30 Oct 2014)
  22. HCC: Case based Discussion, MYSIR2014  (International) (09 Oct 2014 - 11 Oct 2014)
  23. European Society for Medical Oncology (ESMO) 2014-Precision Medicine in Cancer Care, European Society for Medical Oncology (ESMO) 2014-Precision Medicine in Cancer Care, European Society for Medical Oncology  (International) (26 Sep 2014 - 30 Sep 2014)
  24. The progress of the Jakarta Call to Action current and ASEAN member states' plan to improve or deliever effective cancer programs. , 2nd ASEAN Stakeholder Roundtable on Future Access to Cancer Care., The George Institute (International) (25 Apr 2014)
  25. Liver and peritoneal liver metastases , Improving Clinical Outcomes in the Management of Colorectal Cancer-A MDT Workshop (National) (29 Mar 2014)
  26. Cancer Research, Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (30 Nov 2013)
  27. Cancer Services, Annual Scientific Congress in Oncology 2013(Kuala Lumpur)for Malaysian Oncological Society , ASCOMOS 2013 (International) (29 Nov 2013)
  28. Communications Academy for Oncology in Asia, Communications Academy for Oncology in Asia, Boehringer Ingelheim (International) (06 Jul 2013 - 07 Jul 2013)
  29. MESYUARAT JAWATANKUASA KECIL KESELAMATAN (JKK) SINARAN PERUBATAN, KEMENTERIAN KESIHATAN MALAYSIA (KKM) BAGI MEMBINCANGKAN DERAF ATOMIC ENERGY LICENSING (MEDICAL, DENTAL AND VETERINARY USAGE OF RADIATION) REGULATIONS 201_, BIL. 1/2013, MESYUARAT JAWATANKUASA KECIL KESELAMATAN (JKK) SINARAN PERUBATAN, KEMENTERIAN KESIHATAN MALAYSIA (KKM) BAGI MEMBINCANGKAN DERAF ATOMIC ENERGY LICENSING (MEDICAL, DENTAL AND VETERINARY USAGE OF RADIATION) REGULATIONS 201_, BIL. 1/2013, Kementerian Kesihatan Malaysia (National) (28 Jun 2013 - 30 Jun 2013)
  30. ASCO Annual Meeting, ASCO Annual Meeting, ASCO (31 May 2013 - 04 Jun 2013)
  31. Early Breast Cancer Case Challenge and Panel Discussion, 2nd Asia-Pacific Breast Cancer Symposium, Draft Agenda (International) (12 Apr 2013 - 13 Apr 2013)
  32. APAC mCRC Expert Panel meeting , APAC mCRC Expert Panel meeting  (International) (08 Dec 2012)
  33. Roles of Oral Tegafur-Uracil in The Management Of Colorectal Cancer., Breakfast Symposium in Malaysian Oncological Society Annual Conference (ASCOMOS)  (International) (08 Sep 2012)
  34. Discrepancy In Patient And Oncologist-Rated Performance Status On Depression And Anxiety In Cancer: A Prospective Study Protocol, 6th General Assembly of the Asia Pacific Organization for Cancer Prevention , Asian Pacific Organization For Cancer Prevention  (International) (26 Apr 2012 - 29 Apr 2012)
  35. TIMA Convention 2011, TIMA Convention 2011, Taiwan Buddhist Tzu-Chi Foundation Malaysia Kuala Lumpur & Selangor Branch (International) (08 Sep 2011 - 14 Sep 2011)
  36. Opening address by MOS President and Scientific Coordinator (Dr Ho Gwo Fuang), The Art of Oncology Breast Cancer Meeting New Angles, New Facets, New Perspectives (11 Jun 2011 - 12 Jun 2011)
  37. MALAYSIAN ONCOLOGICAL SOCIETY S ANNUAL SCIENTIFIC MEETING, MALAYSIAN ONCOLOGICAL SOCIETY S ANNUAL SCIENTIFIC MEETING, MALAYSIAN ONCOLOGICAL SOCIETY (National) (18 Oct 2008)

ACADEMIC/PROF. SERVICES


Evaluation
  1. (2021) Review Bmge-D-21-00470, 'Intestinal Ulcers in a Patient With Myelodysplastic Syndrome: a Case Report'., International, (Reviewer)
  2. (2021) Review of Manuscript Jmcr-D-20-00967, 'a Rare Case Report of Bullous Pemphigoid Associated With Squamous Cell Lung Carcinoma Showing Remarkable Response to Carboplatin Based Chemotherapy'., International, (Reviewer)
  3. (2021) Review of Manuscript Jmcr-D-20-01407, 'Oral Squamous Cell Carcinoma (Oscc) With Metastase to Brainr is An Unusual Clinical Manifestation: a Case Report'., International, (Reviewer)
  4. (2021) Review of Manuscript Jmcr-D-20-01391r1, 'Hereditary Pheochromocytoma/Paraganglioma Syndrome With a Novel Mutation in The Succinate Dehydrogenase Subunit B (Sdhb) Gene in a Japanese Family: a Case Report'., International, (Reviewer)
  5. (2021) Review of Manuscript Jmcr-D-21-00187, 'Haze of New Treatments in Malignant Disorders Due to Covid-19 Pandemic .Case Series'., International, (Reviewer)
  6. (2021) Review of Manuscript Jmcr-D-19-00863 : Ecchymosis of The Breast as a Rare Late Side Effect of Radiation Therapy: a Case Report, International, (Reviewer)
  7. (2021) Hepatoid Adenocarcinoma of The Lung: a Rare Form of Lung Cancer, International, (Reviewer)
  8. (2021) Review Manuscript "A novel stop codon mutation in exon 5 (c.639G>A) of the CDH1 gene in a Vietnamese man with hereditary diffuse gastric cancer: A case report." in Journal of Medical Case Reports , (Reviewer)
  9. (2021) Review Manuscript "Incidental Finding of Elevated Cartilage Oligomeric Matrix Protein (COMP) in Knee Osteoarthritis Patients with Undiagnosed Colon Cancer: Case Report" in Journal of Medical Case Reports , (Reviewer)
  10. (2021) Review Manuscript "Possible involvement of nesfatin-1/nucleobindin-2 in patients showing pathological complete response after preoperative chemotherapy for breast cancer: case report" in Journal of Medical Case Reports , (Reviewer)
  11. (2021) Review Manuscript "Pyomyositis in a patient undergoing chemotherapy for gastric cancer: a case report and literature review" in Journal of Medical Case Reports , (Reviewer)
  12. (2021) Review Manuscript "Feasibility and efficacy of afatinib for poor performance status patients with EGFR-mutated non-small cell lung cancer." in BMC Cancer, (Reviewer)
  13. (2021) IPT Evaluation Panel, (Evaluators)
  14. (2021) Review Manuscript "Atypical presentation of colorectal carcinoma with sole multiple osteolytic bone metastases: case report" in Journal of Medical Case Reports, (Reviewer)
  15. (2021) Review Manuscript "A case of lung adenocarcinoma concomitant with xeroderma pigmentosum: A case report" in Journal of Medical Case Reports, (Reviewer)
  16. (2020) Pemeriksa dalam Bagi Peperiksaan Peringakat 1 Sarjana Muda Perubatan Dan Sarjana Muda Pembedahan (MBBS) (Utama dan Tambahan) Sesi 2020/2021, (Internal Examiner)
  17. (2020) Review manuscript "Increase in genetic counseling and testing referrals following a breast cancer pathway implementation" in JCO Oncology Practice, (Reviewer)
  18. (2020) Scientific Committee-Masterclass in Systemic Cancer Therapy-Understanding the science behind therapy., (Scientific Committee)
  19. (2020) Review Manuscript "COVID-19 impact on and recommendations for breast cancer care: the Singapore experience for Endocrine-Related Cancer." in Endocrine-Related Cancer , (Reviewer)
  20. (2020) Review Manuscript "A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Colorectal Cancer Patients" in Advances in Therapy , (Reviewer)
  21. (2020) Review manuscript "Phase I study of afatinib plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations." for Translational Lung Cancer Research. , (Reviewer)
  22. (2020) Review manuscript "Increase in genetic counseling and testing referrals following a breast cancer pathway implementation" in JCO Oncology Practice, (Reviewer)
  23. (2019) Review manuscript# JIMR-18-1856 entitled "Effect of Hormone Therapy on Estrogen Receptor- Negative and Progesterone Receptor-Positive Breast Cancer Patients: A Single-center Retrospective Study for Journal of International Medical Research., (Reviewer)
  24. (2019) Extreme IO Case Challenge Premium Edition-6TH Asia Pacific Congress of International Oncology (APCIO) 2019 , (Scientific Committee)
  25. (2019) Best of SABCS2018-8th Asia-Pacific Breast Cancer Summit, (Scientific Committee)
  26. (2019) Live Transmission Leveen RFA for Liver Tumour -6TH Asia Pacific Congress of International Oncology (APCIO) 2019 , (Scientific Committee)
  27. (2019) Review manuscript "Predictors of Quality of Life Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Lutetium Peptide Receptor Radionuclide Therapy" in Journal of Oncology Practice, (Reviewer)
  28. (2019) Lilly Breast Cancer Advisory Board Meeting, (Advisory Committee)
  29. (2019) Honorary Consultant Clinical at Cancer Research Malaysia, (Honorary Consultant Clinical)
  30. (2019) Review journal article "JOP.19.00552, Increase in genetic counseling and testing referrals following a breast cancer pathway implementation" in Journal of Oncology Practice., (Reviewer)
  31. (2018) MIMS Oncology Disease Management Guidelines-Hong Kong 2018/2019, (Advisory Committee)
  32. (2018) Master of Clinical Oncology Part 2 Examination Session 2017/2018, May 2018., (Internal Examiner)
  33. (2018) Lung Advisory Board Meeting Malaysia, (Advisory Committee)
  34. (2018) AstraZeneca EGFRm NSCLC First-Line (FLAURA) Advisory Board, (Advisory Committee)
  35. (2018) Ahli Panel Temuduga bagi Calon Program Ijazah Sarjana Onkologi 2018/2019, (Advisory Committee)
  36. (2018) Review manuscript # IJC-18-0150.R1 "A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial" for the International Journal of Cancer. , (Reviewer)
  37. (2018) Regional unresectable Hepatocellular Carcinoma Advisory Board Meeting, (Advisory Committee)
  38. (2018) Review for BMC Cancer-BCAN-D-17-01285R1 Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells , (Reviewer)
  39. (2018) SD Malaysia Lung Cancer Advisory Board , (Advisory Committee)
  40. (2018) Immuno Oncology: New In Cancer Treatment (ICONIC) Educational Program , (Scientific Committee)
  41. (2018) Review for International Journal of Cancer IJC-18-0150: A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial, (Reviewer)
  42. (2018) Master of Clinical Oncology Final Examination Session 2017/2018, May 2018, (Internal Examiner)
  43. (2017) Pelantikan Pemeriksa Dama Tambahan Bagi Peperiksaan Profesional Peringkat Pengajian 3.2, Sesi 2017/2019, Ijazah Sarjana Muda Perubatan Dan Sarjana Muda Pembedahan, (Internal Examiner)
  44. (2017) Editorial Board Member for Madridge Journal of Clinical Research, (Editor)
  45. (2017) Review for BMC Cancer -BCAN-D-17-00713, (Reviewer)
  46. (2017) Review for BMC Gastroenterology - BMGE-D-16-00467, (Reviewer)
  47. (2017) Review for BMC Cancer -BCAN-D-16-02659R1, (Reviewer)
  48. (2017) Ulasan Pakar ke atas Produk Yang Sedang Dinilai Untuk Pendaftar-Hertraz 440mg Powder for Concentrate, (Advisory Committee)
  49. (2017) Permohonan Tambahan Indikasi Dan Posology Produk Berdaftar-Keytruda 100mg Solution for Infusion , (Advisory Committee)
  50. (2017) Review for BMC Cancer - BCAN-D-17-01285, (Reviewer)
  51. (2017) Master of Clinical Oncology Part 2 Examination Session 2016_2017, (Internal Examiner)
  52. (2017) Review for BMC Cancer - BCAN-D-17-00750, (Reviewer)
  53. (2017) 1st Asian Thoracic Oncology Research Group (ATORG) Scientific Forum, (Advisory Committee)
  54. (2017) Review for BMC Cancer - BCAN-D-16-02787R1, (Reviewer)
  55. (2017) Review for BMC Cancer -BCAN-D-16-02569R1, (Reviewer)
  56. (2017) Review for BMC Cancer - BCAN-D-16-02659 , (Reviewer)
  57. (2017) Asia Pacific Regional Medical Advisory Board on HR+ HER2- mBC, (Advisory Committee)
  58. (2017) Review for BMC Cancer - BCAN-D-17-00735, (Reviewer)
  59. (2017) MSKCC Women / Lung Centre of Excellence, (Advisory Committee)
  60. (2017) Review for BMC Cancer - BCAN-D-16-02787, (Reviewer)
  61. (2015) Master of Clinical Oncology Part 1 Examination 2014/2015, (Internal Examiner)
Media appearance
  1. (2022) The How to Reduce The Recurrent Risk of Breast Cancer, National, (Interview)

SUPERVISION


Postgraduate Student
PhD/ Doctoral
  1. (2021) Explore scientific evidence of Guolin Qigong(GQ), a form of mind-body exercise for survivorship in patient with diagnose of cancer: A mixed methods study., Leng Keng Low (University of Western Sydney)
  2. (2017) DEVELOPMENT OF ELECTROCHEMICAL BIOSENSOR FOR CANCER DIAGNOSTICS, KENNETH LAU E-MING
  3. (2017) Alleviation of Cancer Chemotherapy-Induced Cognitive Impairment and Peripheral Neuropathy via Inhibition of Neuroinflammation and Oxidative Stress by a Standardised Andrographis Paniculata Extract., Nasir Ibrahim Omar Khatab (Universiti Putra Malaysia (UPM))
  4. (2009) Pharmacogenetics of Docetaxel in Malaysian Breast Cancer Patients at University Malaya, Rafid Ewadh (M0100103)
Master
  1. (2018) Clinical Supervision, Annandakumar Balakrishnan
  2. (2018) Clinical Oncology, Chee Yen Hew
  3. (2016) Chemotherapy Induced Nausea And Vomiting And Quality of Life Among Patients Treated With Moderate and Highly Emetogenic Chemotherapy, EZNAL IZWADI MOHD MAHIDIN
  4. (2012) Clinical Supervision, SUCHARIT PONGRAKYUN
  5. (2012) Clinical Supervision, PRATHEPAMALAR A/P YEHGAMBARAN
  6. (2012) Clinical Supervision, EZNAL IZWADI BIN MOHD MAHIDIN
  7. (2012) Clinical Supervision, Ang Tick Suan
  8. (2011) Clinical Supervision, Tang Weng Heng
  9. (2011) Clinical Supervision, Nahjatul Kursyiah Abd Ghafar
  10. (2011) Clinical Supervision, Marfuah Nik Eezamuddeen
  11. (2011) Clinical Supervision, Junie Khoo Yu Yen
  12. (2010) Survival Outcome of Radiosurgery for Unresectable Intracranial Meningioma, Leong Siew Mooi
  13. (2010) Clinical Supervision, Wong Yoke Fui
  14. (2010) Clinical Supervision, Malwinder Singh Sandhu
  15. (2009) Clinical Supervision, Vaishnavi Jeyasingam
  16. (2009) Clinical Supervision, Lim Chun Sen
  17. (2009) Clinical Supervision, Harissa Husainy Hasbullah
  18. (2009) A Phase 2 Trial of Metronomic Chemotherapy in Patients with Endocrine-Resistant Metastatic Breast Cancer with a Partial Response or Stable Disease after Chemotherapy, Muthukkumaran A/L Thiagarajan
  19. (2008) COMPUTED TOMOGRAPHY-BASED 3-DIMENSIONAL TREATMENT PLANNING OF INTRACAVITARY BRACHYTHERAPY FOR CANCER OF THE CERVIX : COMPARISON BETWEEN DOSE-VOLUME HISTOGRAMS AND ICRU POINT DOSES OF THE RECTUM AND BLADDER, Natasha Mohd Hashim
  20. (2008) Clinical Supervision, Suhana Yusak
  21. (2008) Clinical Supervision, Fong Chin Heng
  22. (2008) Clinical Supervision, Cheah Soon Keat
  23. (2007) Clinical Supervision, Lee Wei Ching
  24. (2007) Clinical Supervision, Ibtisam Muhammad Nur
  25. (2007) Clinical Supervision, Hafizah Zaharah Ahmad
  26. (2007) Clinical Supervision, Flora Chong Li Tze
  27. (2006) EVALUATE AND COMPARE TREATMENT OF RFA, TACE AND COMBINED MODALITIES IN UNRESECTABLE HEPATOCELLULAR CARCINOMA -THE UNIVERSITY OF MALAYA MEDICAL CENTRE EXPERIENCE, Ros Suzanna Ahmad Bustamam
  28. (2006) Clinical Supervision, Yu Kong Leong
  29. (2006) Clinical Supervision, Lau Kah Liew
  30. (2006) Clinical Supervision, Hayani Abdul Wahid
  31. (2005) The Histopathology Reports: A Review of the Prognostic Factors and Survival in Colorectal Cancers, Chan Wee Han
  32. (2005) Clinical Supervision, Vincent Phua Chee Ee
  33. (2005) Clinical Supervision, Mastura Md Yusof
  34. (2005) Clinical Supervision, Kua Voon Fong
  35. (2004) Clinical Supervision, Wan Zamaniah Wan Ishak
  36. (2004) Clinical Supervision, Rozita Abdul Malik
  37. (2004) Clinical Supervision, Fabian Lee Wei Yuen
Under Graduate Students
  1. (2019) Mentor for the University of Malaya Medical Programme (UMMP)

TEACHING


Master
  1. (2019) ONCOLOGY - Plan Evaluation
  2. (2019) ONCOLOGY - Viva Pratice
  3. (2019) ONCOLOY - Passing Part 2 Exam: What You Should Know & Oncologic Emergencies
  4. (2018) MID2005 - Basic Medical Science III
  5. (2016) WAES2107 - Master of Clinical Oncology
  6. () ONCOLOGY - Plan Evaluation
Bachelor
  1. (2018) MERDU - Oncology: Decision Making in Cancer
  2. (2018) MERDU - Oncology & Palliative Care :Ethics of Decision Making in Cancer
  3. (2017) MID2005 - Basic Medical Science III

PATENT/IPR


  • Book-Cancer and You
    Copyright (National)

SOCIAL RESPONSIBILITY ACTIVITIES


  • Tzu Chi Cancer Support Group-Nine Years Anniversary, (27 Nov 2022 - 27 Nov 2022) (National)
  • Virtual Amgen Oncology Meeting - McRc Series, (12 Dec 2020 - 12 Dec 2020)
  • Kuala Lumpur Standard Chartered Marathon 2020-Virtual Run 21km, (05 Dec 2020 - 13 Dec 2020)
  • Delegate of Best of Asco-Asco 20 Virtual in Malaysia, (05 Dec 2020 - 06 Dec 2020)
  • 7th Asia Pacific Gastroenterology Cancer Virtual Summit 2020, (22 Aug 2020 - 23 Aug 2020)
  • 4th International Brca Virtual Forum 2020, (21 Aug 2020 - 21 Aug 2020)
  • Covid-19 Preparedness, (22 Jul 2020 - 22 Jul 2020)
  • Jcap Post-Asco Head and Neck Cancer Highlights, (12 Jun 2020 - 12 Jun 2020)
  • 2020 Asco Virtual Scientific Program, (29 May 2020 - 31 May 2020)
  • Majlis Makan Malam Jabatan Onkologi, (11 Aug 2018 - 11 Aug 2018)
  • Score Run-13km, (22 Jul 2018 - 22 Jul 2018)
  • Standard Chartered Kl Marathon 2018-Half Marathon Malaysian Veteran, (08 Apr 2018 - 08 Apr 2018)
  • Penang Bridge International Marathon 2017-Full Marathon, (26 Nov 2017 - 26 Nov 2017)
  • Tima Kampung Juru Bukit Mertajam Flood Relief, (12 Nov 2017 - 12 Nov 2017)
  • The 3rd Blue Cap Relay Run for Prostate Cancer 2017, (24 Sep 2017 - 24 Sep 2017)
  • Imu Chariofare 2017-5km Run, (16 Sep 2017 - 16 Sep 2017)
  • Ijm Npe Highway Challenge-Half Marathon Challenge Run, (10 Sep 2017 - 10 Sep 2017)
  • Guardians of The District - Malaysia Independence Day 2017, 10km Run, (31 Aug 2017 - 04 Sep 2017)
  • Fit Malaysia-10km Run, (12 Aug 2017 - 12 Aug 2017)
  • Pj Half Marathon 2017, (23 Jul 2017 - 23 Jul 2017)
  • Fathers Day Virtual Run-10km, (16 Jun 2017 - 18 Jun 2017)
  • Standard Chartered Kl Virtual Marathon-Half Marathon, (21 May 2017 - 21 May 2017)
  • Coway Run-10km, (07 May 2017 - 07 May 2017)
  • Score Run-Conquer The City 2017, (09 Apr 2017 - 09 Apr 2017)
  • Grand Opening Performances-Tima (Tzu Chi International Medical Association) Conference 2017, (17 Mar 2017 - 17 Mar 2017)
  • Shine Resolution Run 2017, (22 Jan 2017 - 22 Jan 2017)
  • 2nd Blue Cap Relay Run for Prostate Cancer-Run With Your Man, (06 Nov 2016 - 06 Nov 2016)
  • 13th Humanistik Charity Run-Nationwide Charity Run for Needy Students, (23 Oct 2016 - 23 Oct 2016)
  • Tzuchi,Waterdharma, (03 Jul 2015 - 05 Jul 2015)
  • Flood Relief Visit At Kuala Krau With Tzu Chi International Medical Association (Tima), (11 Jan 2015 - 11 Jan 2015)
  • Ntv7 Program,Global Watch,How to Prevent Radiation? 09 Oct 2013., (09 Oct 2013)
  • Breast Cancer Awareness Shooting Program,18 September 2013., (18 Sep 2013)
  • Tzu Chi Health Screening, (30 Jun 2013)
  • Tzu Chi Health Screening, (09 Sep 2012 - 09 Sep 2012)
  • Tzu Chi Health Screening, (26 Dec 2010)